Document:

EX-10.20

 Exhibit 10.20 

Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly
disclosed. 
 EXECUTION VERSION 

ASSIGNMENT AND LICENSE AGREEMENT 

This Assignment and License Agreement (this “Agreement”) is made and entered into as of November 5, 2018 (the
“Effective Date”) by and between Mirum Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (“Mirum”), and Shire International GmbH, a company organized under the laws
of Switzerland (“Shire”). Mirum and Shire are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 
 A.
Shire, through the acquisition of Lumena Pharmaceuticals, Inc. (now Lumena Pharmaceuticals LLC, “Lumena”), controls certain intellectual property related to the Compounds, including through
in-licenses under the Assigned License Agreements. 
 B. Mirum is a privately-held
biotechnology company focused on developing treatments for orphan diseases. 
 C. Mirum desires to acquire an exclusive worldwide
license under intellectual property owned by Shire or its Affiliates related to the Compounds to develop, manufacture and commercialize Licensed Products for use in the Field, and Shire is willing to grant such a license to Mirum, on the terms and
conditions set forth herein. 
 D. Mirum desires to receive an assignment of the Assigned Agreements, and Shire is willing to make
such assignment to Mirum, on the terms and conditions set forth herein. 
 E. Simultaneously with the execution and delivery of this
Agreement, the Parties are entering into Investment Agreements with respect to an issuance of common stock by Mirum to Shire (or its Affiliate). 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this
Agreement, the Parties agree as follows: 
  

	1.	 DEFINITIONS 

Capitalized terms used in this Agreement (other than the headings of the Sections or Articles) have the following meanings set forth in this
Article 1, or, if not listed in this Article 1, the meanings as designated in the text of this Agreement. 
 1.1
“Affiliate” means, with respect to a particular Party, a person, corporation, partnership, or other entity that controls, is controlled by or is under common control with such Party. For the purposes of the definition in this
Section 1.1, the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through
one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of at least fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. 

 1.2 “ALGS Indication” means (a) any Indication for Alagille
Syndrome or (b) any Indication based on clinical studies in patients with Alagille Syndrome (e.g., pruritus based on trials in patients with Alagille Syndrome). 

1.3 “ASBT Inhibition Activity” means the inhibition of bile acid absorption through the apical sodium-dependent bile
acid transporter (ASBT), also known as ileal bile acid transporter (IBAT), ileal sodium-dependent bile acid transporter (ISBT), or Na+-taurocholate cotransporting polypeptide (NTCP2). 

1.4 “Assigned Agreements” means the Assigned Ancillary Agreements and the Assigned License Agreements. 

1.5 “Assigned Ancillary Agreements” means the Development and Pre-Commercial
Supply Agreement by and between Shire Orphan and Rare Diseases GmbH (“SORD”) (which subsequently merged into Shire, with Shire being the surviving entity and assuming all SORD’s assets and liabilities by universal succession
under Swiss law) and Sanofi, effective September 16, 2016. 
 1.6 “Assigned License Agreements” means the Pfizer
Agreement, the Satiogen Agreement and the Sanofi Agreement. 
 1.7 “Biliary Atresia Indication” means (a) any
Indication for biliary atresia, also known as extrahepatic ductopenia or progressive obliterative cholangiopathy or (b) any Indication based on clinical studies in patients with biliary atresia, also known as extrahepatic ductopenia or
progressive obliterative cholangiopathy (e.g., pruritus based on trials in patients with biliary atresia). 
 1.8 “CMC
Activities” means the activities necessary or useful for generating the Information related to the chemistry, manufacturing and controls of Compound or Licensed Product required for the Regulatory Approval of Licensed Products, as specified
by the FDA or other applicable Regulatory Authority. 
 1.9 “Combination Product” means any Licensed Product that
consists of a Compound and at least one other active pharmaceutical ingredient that is not a Compound (“Other Active Ingredient”). 

1.10 “Commercialize” means to promote, market, distribute, sell, offer for sale, contract to sell, export or import
Licensed Product. For clarity, “Commercializing” and “Commercialization” have a correlative meaning. 

1.11 “Commercially Reasonable Efforts” means, with respect to Mirum’s obligations under this Agreement, the
carrying out of such obligations or tasks with a level of efforts and resources consistent with the commercially reasonable practices in the pharmaceutical industry for a similarly situated pharmaceutical product as the Licensed Product at a similar
stage of development or commercialization, taking into account efficacy, safety, patent and regulatory 

  
 2 

 
exclusivity, anticipated or approved labeling, present and future market potential, competitive market conditions, the profitability of the Licensed Product in light of pricing and reimbursement
issues, and other relevant factors. Commercially Reasonable Efforts shall be determined on a market-by-market and indication-by-indication basis, and it is anticipated that the level of efforts required shall be different for different markets and indications and shall change over time, reflecting changes in the
regulatory status of the Licensed Product and markets involved. 
 1.12 “Compound” means (a) the compound known
as SHP625 (maralixibat) with the structure set forth on Exhibit 1.12(a) and any [...***...] (the “SHP625 Compound”) or (b) the compound known as SHP626 (volixibat) with the structure set forth on Exhibit
1.12(b) and [...***...] (the “SHP626 Compound”); provided that in each case of foregoing clauses (a) and (b), such compound has ASBT Inhibition Activity. 

1.13 “Confidential Information” of a Party means any and all Information of such Party that is disclosed to the other
Party or its Affiliates under this Agreement (or that was disclosed under the Existing Confidentiality Agreement or any other confidentiality agreements between the Parties or their Affiliates), whether in oral, written, graphic, or electronic form.

 1.14 “Controlled” means, with respect to any compound, material, Information or intellectual property right, that
a Party owns or has a license to such compound, material, Information or intellectual property right and has the ability to grant to the other Party access, a license or a sublicense (as applicable) to such compound, material, Information or
intellectual property right as provided for herein without violating the terms of any agreement or other arrangements with any Third Party existing at the time such Party would be first required hereunder to grant the other Party such access,
license or sublicense. Notwithstanding the foregoing, no compound, material, Information or intellectual property right shall be considered Controlled by Shire if a grant of access, license or sublicense to Mirum requires or triggers a payment
obligation of Shire or its Affiliates. 
 1.15 “Develop” or “Development” means, with respect to
Compounds and Licensed Products, all activities relating to preparing and conducting non-clinical studies and other analyses, clinical studies, and regulatory activities (e.g., preparation and submission of
regulatory applications) that are necessary or useful to obtain or maintain Regulatory Approval of Licensed Products, excluding Manufacturing. 

1.16 “Dollars” or “$” means the legal tender of the U.S. 

1.17 “EMA” means the European Medicines Agency or any successor entity. 

1.18 “EU” means the European Union, including the United Kingdom and other countries in the European Union as of the
Effective Date regardless of continuing membership, and any additional countries subsequently joining its membership as may be added from time to time, and any successor thereto. 

1.19 “Executive Officers” means the Chief Executive Officer of Mirum and the Head of Corporate Development for Shire,
or such other person (of similar seniority within Shire) designated by Shire from time to time. 

  
 3 

 1.20 “Existing Confidentiality Agreement” means that certain
Confidentiality Agreement by and between Mirum and Shire Human Genetic Therapies, dated as of May 2, 2018, as amended August 8, 2018. 

1.21 “FDA” means the U.S. Food and Drug Administration, and any successor thereto. 

1.22 “FFDCA” means the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §301 et seq., as amended from
time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto). 

1.23 “Field” means any therapeutic or prophylactic application in human (but not animal) health. 

1.24 “First Commercial Sale” means, with respect to a Licensed Product in a particular country, the first commercial
sale of such Licensed Product in such country after Regulatory Approval has been obtained in such country. 
 1.25
“GAAP” means U.S. generally accepted accounting principles consistently applied. 
 1.26 “Generic
Product” means, with respect to a Licensed Product being sold by Mirum or its Affiliates or their sublicensees, as applicable, any product containing the same Compound as such Licensed Product (and the same Other Active Ingredient(s), as
applicable, in the case of a Combination Product), which is marketed by an entity other than Mirum and its Affiliates or their sublicensees in the Field. A Licensed Product licensed or produced by Mirum, its Affiliates or their respective
sublicensees (i.e., an authorized generic product) will not constitute a Generic Product. 
 1.27 “Governmental
Authority” means any multi-national, federal, state, local, municipal, provincial or other government authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office,
commission, council, court or other tribunal). 
 1.28 “Indication” means any disease or condition which could be
listed under the header “INDICATIONS AND USAGE” or a subset of any disease or condition which could be listed under the header “INDICATIONS AND USAGE” of a Licensed Product’s label upon Regulatory Approval in the U.S., or
equivalent thereof in or outside the U.S. 
 1.29 “Information” means all information, techniques, technology,
practices, trade secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, data, specifications, results (including pharmacological, toxicological and clinical test data
and results), analytical and quality control data, results or descriptions, software and algorithms. 
 1.30
“Initiation” of a clinical trial (including a Phase 2 Clinical Trial and a Phase 3 Clinical Trial) means the first randomization of a subject enrolled in such clinical trial. 

  
 4 

 1.31 “Knowledge” means, with respect to a Party, the good faith
understanding of the facts and information in the possession of an officer of such Party, or any in-house legal counsel of, or in-house patent agents employed by, such
Party or its Affiliates, without any duty to conduct any additional investigation with respect to such facts and information by reason of the execution of this Agreement. For purposes of this definition, an “officer” means any person in
the position of vice president, senior vice president, president or chief executive officer of a Party. 
 1.32
“Laws” means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or
foreign. 
 1.33 “Licensed Product” means (a) any pharmaceutical product in any dosage strength or formulation
that is or contains a Compound, either alone or in combination with one or more other agents and (b) any “Licensed Product” as such term is defined in the Sanofi Agreement, Satiogen Agreement or Pfizer Agreement. 

1.34 “Major Markets” means [...***...]. 

1.35 “Manufacturing” means all activities (including CMC Activities) related to the manufacture of Compounds and
Licensed Products, including formulation, processing, filling, finishing, packaging, labeling, inspection, receiving, holding, and shipping of Compound, Licensed Product, or any raw materials or packaging materials with respect thereto, or any
intermediate of any of the foregoing, and including process and cost optimization, process development, qualification and validation, equipment and facility qualification and validation, commercial manufacture of Licensed Product, stability and
release testing, quality assurance and quality control with respect to Licensed Product. For clarity, “Manufacture” has a correlative meaning. 

1.36 “Marketing Authorization Application” or “MAA” means: (a) in the U.S., a New Drug
Application (as defined in the FFDCA) or any supplement to a New Drug Application, and (b) in any other country or regulatory jurisdiction, an equivalent application for regulatory approval required before commercial sale or use of a
pharmaceutical product (or with respect to a subsequent Indication) in such country or regulatory jurisdiction, including, in the EU a Marketing Authorization Application filed pursuant to a centralized procedure. 

1.37 “Net Sales” means, with respect to a Licensed Product a given period of time, the gross amount invoiced by Mirum,
its Affiliates or their respective sublicensees to Third Party purchasers from the sale or distribution to such Third Parties of the Licensed Product, less the following deductions and offsets that are actually incurred, allowed, accrued or taken
and are specifically allocated with respect to such sale or distribution, but solely to the extent that such deductions or offsets are not otherwise recovered by or reimbursed to Mirum, its Affiliates or their respective sublicensees: 

 

	 	(a)	 [...***...]; 

  

	 	(b)	 [...***...]; 

  
 5 

	 	(c)	 [...***...]; 

  

	 	(d)	 [...***...]; and 

 

	 	(e)	 [...***...]. 

The methodology for calculating (a) – (e), on a
country-by-country basis, shall conform to GAAP consistently applied by Mirum. 

Net Sales shall also include the fair market value of all consideration received by Mirum, its Affiliates or their respective sublicensees in
respect of any sale of Licensed Product to Third Party end-users, whether such consideration is in cash, payment in kind, exchange for value, or any other form. 

If any discounts or other deductions or rebates are made in connection with sales of a Licensed Product that is bundled or sold together with
other products of Mirum, its Affiliates or their respective sublicensees, then the discount, deduction or rebate applied to the Licensed Product shall not exceed the discount, deduction or rebate applied to any of the other products of Mirum, its
Affiliates, or their respective sublicensees in such arrangement based upon the respective list prices of the Licensed Product and such other products prior to applying the discount, unless Mirum provides evidence reasonably satisfactory to Shire
that such difference is commercially reasonable and does not unfairly prejudice the Licensed Product in favor of such other products. 
 For
Licensed Products which are sold as Combination Products, the Net Sales for such Combination Products shall be adjusted by multiplying the actual Net Sales by the fraction A/(A+B) where A is [...***...], and B is [...***...]. If the
Other Active Ingredient is not sold separately, then the actual Net Sales shall be adjusted by multiplying the actual Net Sales by the fraction A/C where A is [...***...], and C is [...***...]. If neither of the foregoing applies, then
the Parties shall determine the Net Sales of the Combination Product in good faith based on the respective values of the components of such Combination Product. If the Parties are not able to reach agreement, Net Sales for such Combination Product
shall be determined by an expert jointly appointed by the Parties, with such determination to be based on the respective values of the components of such Combination Product. The decision of the expert shall be final and binding on the Parties, and
the fees of the expert shall be equally shared between the Parties. 
 1.38 “Other Indication” means any Indication
in the Field other than a PFIC Indication, ALGS Indication, or Biliary Atresia Indication, provided that a Regulatory Approval or label expansion for such Indication (a) would not be solely to treat an expanded set of patients for a previously
approved disease or medical condition and (b) would not be solely for use as a different line of therapy for the previously approved disease or medical condition. 

1.39 “Patent” means all: (a) unexpired letters patent (including inventor’s certificates), including any
substitution, extension, registration, confirmation, validation, reissue, re-examination, supplementary protection certificates, confirmation patents, patent of additions, renewal or any like filing thereof,
in each case which have not been held invalid or unenforceable by a court of competent jurisdiction from which no appeal can be taken or has been taken within the required time period (and which have not been admitted to be invalid or unenforceable
through 

  
 6 

 
reissue, disclaimer or otherwise, and have not been abandoned in accordance with or as permitted by the terms of this Agreement or by mutual written agreement); (b) pending applications for
letters patent which have not been canceled, withdrawn from consideration, finally determined to be unallowable by the applicable governmental authority or court for whatever reason (and from which no appeal is or can be taken), or abandoned in
accordance with or as permitted by the terms of this Agreement or by mutual written consent, including any continuation or division thereof and any provisional applications; and (c) any U.S. and international counterparts to any of (a) and
(b) above. 
 1.40 “PFIC Indication” means (a) any Indication for progressive familial intrahepatic cholestasis
or (b) any Indication based on clinical studies in patients with progressive familial intrahepatic cholestasis (e.g., pruritus based on trials in patients with progressive familial intrahepatic cholestasis). 

1.41 “Pfizer Agreement” means that certain License Agreement by and between Lumena (thereafter assigned to Shire) and
Pfizer Inc. (“Pfizer”), dated as of June 1, 2012. 
 1.42 “Pfizer
Know-How” means the Licensed Know-How (as defined in the Pfizer Agreement). 

1.43 “Phase 2 Clinical Trial” means a study of a Licensed Product in the Field in human patients to determine safety
and efficacy, pharmacological effect, or dose range or regimen finding before embarking on Phase 3 Clinical Trial, as further defined in 21 C.F.R. 312.21(b), as amended from time to time, or the corresponding foreign regulations. 

1.44 “Phase 3 Clinical Trial” means a pivotal study (whether or not denominated a “Phase 3” clinical study
under applicable regulations) in the Field in human patients with a defined dose or a set of defined doses of a Licensed Product designed to ascertain efficacy and safety of such Licensed Product for the purpose of enabling the preparation and
submission of Marketing Authorization Applications to the competent Regulatory Authorities in a country of the Territory, as further defined in 21 C.F.R. 312.21(c), as amended from time to time, or the corresponding foreign regulations. 

1.45 “Regulatory Approval” means any and all approvals, licenses, registrations or authorizations of any national,
supra-national (e.g., the European Commission or the Council of the EU), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, that are necessary for the distribution or sale of a Licensed
Product in a regulatory jurisdiction. For clarity, Regulatory Approval does not include pricing or reimbursement approval. 
 1.46
“Regulatory Authority” means the applicable national (e.g., the FDA), supra-national (e.g., the European Commission or the Council of the EU), regional, state or local regulatory agency, department, bureau, commission, council or
other governmental entity that, in each case, governs the approval of a Licensed Product in such applicable regulatory jurisdiction. 

  
 7 

 1.47 “Regulatory Exclusivity” means, with respect to any country or
other jurisdiction in the Territory, an additional market protection, other than Patent protection, in such country or other jurisdiction which confers an exclusive period during which Mirum or its Affiliates or their respective sublicensees have
the exclusive right to market or sell a Compound or Licensed Product in such country or other jurisdiction through a regulatory exclusivity right, including new chemical entity exclusivity, new use or indication exclusivity, new formulation
exclusivity, orphan drug exclusivity, pediatric exclusivity, or any applicable data exclusivity. 
 1.48 “Regulatory
Materials” means regulatory applications, submissions, notifications, registrations, Regulatory Approvals or other filings made to or with, or other approvals granted by, a Regulatory Authority that are necessary or reasonably desirable in
order to Develop, Manufacture, market, sell, or otherwise Commercialize a Licensed Product in a particular country or regulatory jurisdiction. 

1.49 “Royalty Patents” means Shire Patents, Sanofi Patents and Satiogen Patents. 

1.50 “Sales Tax” means all forms of taxes, levies, and charges levied by Governmental Authorities relating to the
purchase of tangibles or services, the cost of which is borne by the purchaser together with successor or replacement taxes levied by reference to the sale of goods or services. 

1.51 “Sanofi Agreement” means that certain License Agreement by and between Lumena (thereafter assigned to Shire) and
Sanofi-Aventis Deutschland GmbH (“Sanofi”), dated as of September 27, 2012, as amended by that certain Amendment No. 1 to License Agreement by and between Lumena and Sanofi, dated as of June 26, 2015. 

1.52 “Sanofi Know-How” means the Sanofi
Know-How (as defined in the Sanofi Agreement). 
 1.53 “Sanofi Patents” means
the Sanofi Patents (as defined in the Sanofi Agreement), including the Patents set forth on Exhibit 1.53. 
 1.54
“Satiogen Agreement” means that certain License Agreement by and between Lumena (thereafter assigned to Shire) and Satiogen Pharmaceuticals, Inc. (“Satiogen”), dated as of February 8, 2011, as amended by that
certain Letter Agreement by and between Lumena and Satiogen, dated as of March 18, 2017. 
 1.55 “Satiogen Know-How” means the ASBTi Know-How (as defined in the Satiogen Agreement). 

1.56 “Satiogen Patents” means the ASBTi Patents (as defined in the Satiogen Agreement), including the Patents set forth
on Exhibit 1.56. 
 1.57 “Shire IP” means the Shire Patents and the Shire
Know-How. 
 1.58 “Shire Know-How”
means all Information Controlled by Shire or its Affiliates as of the Effective Date that are necessary or reasonably useful for development, manufacture, use, sale, offer for sale, or importing of any SHP625 Licensed Product or SHP626 Licensed
Product. The Shire Know-How expressly excludes the Pfizer Know-How, Sanofi Know-How and Satiogen
Know-How. 

  
 8 

 1.59 “Shire Patents” means, (a) any Patents Controlled by Shire
or its Affiliates as of the Effective Date that are necessary or reasonably useful for development, manufacture, use, sale, offer for sale, or importing of any SHP625 Licensed Product or SHP626 Licensed Product, which Patents are set forth on
Exhibit 1.59, and (b) any Patents claiming priority to the Patents in foregoing clause (a). The Shire Patents expressly exclude the Sanofi Patents and Satiogen Patents. 

1.60 “Territory” means all countries in the world. 

1.61 “Third Party” means any person or entity other than: (a) Mirum; (b) Shire; or (c) an Affiliate of either
Party. 
 1.62 “U.S.” means the United States of America, including all possessions and territories thereof. 

1.63 “Valid Claim” means (a) a claim in an issued Patent that has not: (i) expired or been canceled;
(ii) been declared invalid by an unreversed and unappealable or unappealed decision of a court or other appropriate body of competent jurisdiction; (iii) been admitted to be invalid or unenforceable through reissue, disclaimer or
otherwise; or (iv) been abandoned in accordance with or as permitted by the terms of this Agreement or by mutual written agreement of the Parties; or (b) a claim under an application for a Patent that has not been canceled, withdrawn from
consideration, finally determined to be unallowable by the applicable governmental authority or court for whatever reason (and from which no appeal is or can be taken), or abandoned. 

1.64 “VAT” shall mean (a) in relation to any jurisdiction within the European Union, the tax imposed by the EC
Council Directive on the common system of value added tax (2006/112/EC) and any successor or equivalent legislation and any national legislation implementing that directive together with legislation supplemental thereto and the equivalent tax (if
any) in that jurisdiction and (b) in any other jurisdiction, any other value added, goods and services, consumption, or similar tax chargeable on the supply or deemed supply of goods or services under applicable legislation or regulation; but,
in each event, excluding any Sales Tax. 
 1.65 Additional Definitions. Each of the following definitions is set forth in the
section of the Agreement indicated below: 
  

			
	 Definition
	  	 Section

	“Acquiror”	  	12.4
	“Acquiror Affiliates”	  	3.6(b)
	“Agreement”	  	Preamble
	“Alliance Manager”	  	5.1
	“Arising IP”	  	6.1
	“Arising Patents”	  	6.1
	“Change in Control”	  	3.6(b)
	“Claims”	  	10.1(a)
	“Competing Product”	  	3.6(a)(i)
	“Complementary Product”	  	3.6(a)(iii)

  
 9 

			
	 Definition
	  	 Section

	“Development Plan”	  	5.2(b)
	“Effective Date”	  	Preamble
	“Existing Trials”	  	5.3(b)
	“FCPA”	  	5.5(c)
	“Generic Entry”	  	4.5(d)(iv)
	“ICC”	  	11.3
	“Indemnified Party”	  	10.1(c)
	“Indemnifying Party”	  	10.1(c)
	“Investment Agreements”	  	4.2
	“Lumena”	  	Recitals
	“Market Share”	  	4.5(d)(iv)
	“Mirum”	  	Preamble
	“Mirum Indemnities”	  	10.1(b)
	“Mirum Withholding Tax Action”	  	4.9(d)
	“Other Active Ingredient”	  	1.9
	“Other Licensed Products”	  	4.5(a)
	“Party” and “Parties”	  	Preamble
	“Pfizer”	  	1.41
	“Product Failure”	  	3.6(a)(ii)
	“Product Infringement”	  	6.3(a)
	“Product Marks”	  	5.5(b)
	“Royalty Term”	  	4.5(b)
	“Sanofi”	  	1.51
	“Satiogen”	  	1.54
	“SEC”	  	7.4(b)
	“Shire”	  	Preamble
	“Shire Indemnitees”	  	10.1(a)
	“SHP625 Compound”	  	1.12
	“SHP625 Licensed Product”	  	4.3(a)
	“SHP626 Compound”	  	1.12
	“SHP626 Licensed Product”	  	4.3(b)
	“Term”	  	8.1
	“Third Party Claim”	  	4.5(d)(iii)
	“Third Party License”	  	4.5(d)(iii)
	“Transition Services Agreement”	  	5.2(d)
	“Upfront Payment”	  	4.1

  

	2.	 ASSIGNMENT 

2.1 Assigned Agreements. Shire hereby assigns, transfers and conveys to Mirum all of Shire’s and its Affiliates’ right,
title and interest in and to the Assigned Agreements and Mirum hereby (a) accepts such assignment, transfer and conveyance and agrees to timely perform, pay and discharge, as and when due, all duties and obligations of Shire and its Affiliates
(Mirum and its Affiliates after assignment) under the Assigned Agreements to the extent arising on or after the 

  
 10 

 
Effective Date and excluding all liabilities arising from any failure by Shire or its Affiliates to timely perform, pay and discharge, as and when due, all duties and obligations of Shire and its
Affiliates under the Assigned Agreements prior to the Effective Date, which shall remain liabilities of Shire or its Affiliates, and (b) agrees to be substituted for Shire or its Affiliate, as applicable, as a party to the Assigned Agreements
from and after the Effective Date; provided, however, to the extent that any Assigned License Agreements cannot be assigned, transferred and conveyed to Mirum, Section 2.2 shall apply. For clarity, regardless of whether any residual license
rights are granted under Section 2.2 under an Assigned License Agreement pending any assignment, transfer or conveyance of such Assigned License Agreement, Mirum shall be responsible for all payment obligations under such Assigned License
Agreement, including reimbursement of any patenting costs and payments of any royalties and milestones required thereunder, that become due and payable on or after the Effective Date, but excluding all payment obligations arising from any failure by
Shire or its Affiliates to timely perform, pay and discharge, as and when due, any payment obligations or other duties and obligations of Shire and its Affiliates under the Assigned Agreements prior to the Effective Date, which shall remain
liabilities of Shire or its Affiliates; provided, however, that notwithstanding anything to the contrary herein, Shire shall be responsible for all payment obligations under the Assigned License Agreements that become due and payable whether on or
after the Effective Date by virtue of payment of the Upfront Payment or issuance of Common Stock pursuant to the Investment Agreements to Shire or its Affiliates. 

2.2 Residual License. To the extent that any Assigned License Agreements cannot be assigned, transferred and conveyed to Mirum
pursuant to Section 2.1, then until such assignment, transfer and conveyance to Mirum is effected, the following shall apply with respect to such Assigned License Agreements only: 

(a) Assigned License Agreement IP. Subject to the terms and conditions of this Agreement including Section 2.2(b), Shire
hereby grants to Mirum during the Term an exclusive (even as to Shire, but subject to Section 3.3), royalty-bearing sublicense, with the right to further sublicense through multiple tiers as provided in Section 3.2, under the Pfizer Know-How (if the Pfizer Agreement is subject to this Section 2.2), the Sanofi Know-How and Sanofi Patents (if the Sanofi Agreement is subject to this Section 2.2),
or the Satiogen Know-How and Satiogen Patents (if the Satiogen Agreement is subject to this Section 2.2), in each case to develop, have developed, make, have made, use, sell, have sold, offer for sale, or
import Licensed Products in the Territory. If not previously exercised by Shire or its Affiliates, Mirum shall have the exclusive right to exercise the Compound Manufacturing Option under the Sanofi Agreement, and Shire shall cooperate with Mirum
(at no cost to Shire) if Mirum provides written notice to Shire that it wishes to exercise such Compound Manufacturing Option to the extent necessary to effect such exercise. 

(b) Compliance with the Pfizer Agreement, Sanofi Agreement or Satiogen Agreement, as Applicable. The sublicenses to Mirum under
Section 2.2(a), and any right of Mirum to grant a further sublicense thereunder, shall be subject and subordinate to the terms and conditions of the Pfizer Agreement, Sanofi Agreement, or Satiogen Agreement, as applicable, and shall be
effective solely to the extent permitted under the terms of such agreement(s). Without limiting the foregoing, if and to the extent the Pfizer Agreement, Sanofi Agreement or Satiogen Agreement, as applicable, (a) contains terms and conditions
that provide to Shire the right to grant sublicenses (i) for a field of use that is narrower in any respect than the Field, (ii) for a territory 

  
 11 

 
that is narrower in any respect than the Territory, or (iii) with respect to a compound or product, the definition of which is more limited than Compound or Licensed Product, respectively,
the sublicenses granted by Shire to Mirum under Section 2.2(a) shall be deemed to permit Mirum to exercise such sublicense only with respect to such more limited compound or product, or such narrower field or territory, as applicable, each as
defined in the Pfizer Agreement, Sanofi Agreement or Satiogen Agreement, as applicable (and, for clarity, in no event shall the scope of any definition or terms under the Pfizer Agreement, Sanofi Agreement, or Satiogen Agreement expand the
Compounds, Licensed Products or Field hereunder), or (b) requires that particular terms or conditions be contained or incorporated in any agreement granting a sublicense thereunder, such terms and conditions are hereby deemed to be incorporated
herein by reference to the extent applicable to the sublicense granted herein under the Pfizer Agreement, Sanofi Agreement, or Satiogen Agreement, as applicable. Mirum shall remain responsible for the compliance with the Pfizer Agreement, Sanofi
Agreement, and Satiogen Agreement by any such sublicensee. So long as any sublicense granted by Shire to Mirum under Section 2.2(a) remains in effect, Shire and its Affiliates shall not amend or terminate the Pfizer Agreement, Sanofi Agreement,
or Satiogen Agreement, as applicable, except with the prior written consent of Mirum, not to be unreasonably withheld, delayed or conditioned. 

(c) Efforts to Complete Assignment. If Pfizer, Sanofi or Satiogen notify Shire or Mirum in writing that the assignment, transfer
and conveyance of the Pfizer Agreement, Sanofi Agreement, or Satiogen Agreement, respectively, to Mirum hereunder requires their consent or is otherwise not effective, then Shire and its Affiliates will use commercially reasonable efforts, and Mirum
will reasonably cooperate with Shire’s efforts, to obtain such consent or take other reasonable actions (at no cost to Shire) in order to complete the assignment, transfer and conveyance of the Pfizer Agreement, Sanofi Agreement, or Satiogen
Agreement, as applicable, to Mirum pursuant to Section 2.1. 
 2.3 Notice of Assigned Agreements. In addition, promptly
after the Effective Date, (a) Shire shall provide written notice to Sanofi of the assignment to Mirum of the Sanofi Agreement and Mirum shall countersign such notice acknowledging Mirum’s express assumption as of the Effective Date of
performance of Shire’s and its Affiliates rights and obligations under the Sanofi Agreement as required by Section 12.4 of the Sanofi Agreement, (b) Shire shall provide written notice to Sanofi of the assignment to Mirum of the
Assigned Ancillary Agreement and Mirum shall countersign such notice acknowledging Mirum’s express assumption as of the Effective Date of performance of Shire’s and its Affiliates rights and obligations under the Assigned Ancillary
Agreement as required by Section 12.4 of the Sanofi Agreement (which is cross referenced in the Assigned Ancillary Agreement) (c) Shire shall provide written notice to Satiogen of the assignment to Mirum of the Satiogen Agreement and Mirum
shall countersign such notice acknowledging Mirum’s agreement be bound by the Satiogen Agreement as of the Effective Date as required by Section 10.10 of the Satiogen Agreement, and (d) Shire shall provide written notice to Pfizer of
the assignment to Mirum of the Pfizer Agreement. 

  
 12 

	3.	 LICENSES AND RELATED RIGHTS 

3.1 License Grants. 

(a) Shire IP. Subject to the terms and conditions of this Agreement, Shire hereby grants Mirum during the Term an exclusive (even
as to Shire, but subject to Section 3.3), royalty-bearing license, with the right to sublicense through multiple tiers as provided in Section 3.2, under the Shire IP, in each case to develop, have developed, make, have made, use, sell,
have sold, offer for sale, or import SHP625 Licensed Products and SHP626 Licensed Products in the Territory. 
 (b) Regulatory
Materials. Subject to the terms and conditions of this Agreement, Shire hereby grants Mirum during the Term an exclusive (even as to Shire, but subject to Section 3.3), royalty-bearing license and right of reference, with the right to
sublicense through multiple tiers as provided in Section 3.2, under the Regulatory Approvals and any other Regulatory Materials Controlled by Shire or its Affiliates as of the Effective Date, in each case to develop, have developed, make, have
made, use, sell, have sold, offer for sale, or import the SHP625 Licensed Products and SHP626 Licensed Products in the Territory. 

3.2 Sublicensing; Subcontracting. Mirum shall have the right to grant sublicenses of the license granted to it under
Section 3.1 and, to the extent applicable, Section 2.2, or otherwise subcontract its activities with respect to the Compounds or Licensed Products, to its Affiliates and any Third Parties; provided that: (a) Mirum shall remain
responsible for the compliance with this Agreement by any such sublicensee or subcontractor; (b) each such sublicense or subcontract agreement shall be consistent with the terms and conditions of this Agreement; and (c) Mirum shall ensure
that it obtains ownership or licenses or rights to all inventions and Information (including all data, know-how, inventions, Regulatory Materials and Regulatory Approvals) generated by such sublicensee or
subcontractor under such agreement that are related to the applicable Licensed Product and are sufficient to enable Mirum to grant the rights granted to Shire hereunder, including Shire’s rights under Section 8.6. Upon termination of this
Agreement, other than by Mirum pursuant to Section 8.2 or 8.5, all such sublicense agreements shall survive such termination and automatically convert to a direct license or sublicense between Shire and the sublicensee solely if all of the
following apply: (i) such direct license or sublicense is consistent with, and not in conflict with, the terms of this Agreement and is as protective of Shire (and, in the case of indemnification, the Shire Indemnitees) as this Agreement,
(ii) the sublicensee under such sublicense agreement is not in breach of such sublicense agreement at the time of such termination of this Agreement, (iii) Shire has no obligations or liabilities under such direct license or sublicense
beyond the obligations and liabilities of Shire under this Agreement, and (iv) the milestones and royalties to be paid to Shire under such direct license or sublicense are no less favorable to Shire than those to be paid to Shire under this
Agreement. 
 3.3 Retained Rights. Notwithstanding anything to the contrary, Shire retains the right to practice the Shire IP
outside the scope of the licenses granted to Mirum in Section 3.1 and, to the extent applicable, Section 2.2. 
 3.4
Negative Covenant. Mirum covenants that it will not, and will not permit any of its Affiliates or their respective sublicensees or subcontractors, to use or practice any Shire IP outside the scope of the licenses granted to it under
Section 3.1. 

  
 13 

 3.5 No Implied Licenses. Except as explicitly set forth in this Agreement,
neither Party nor its Affiliates has granted nor shall be deemed to have granted (whether by estoppel, implication or otherwise) to the other Party any license or other right to any materials or intellectual property of such Party. 

3.6 Exclusivity. 

(a) Mirum agrees that, except for the Development and Commercialization of Licensed Products pursuant to this Agreement and the Assigned
Agreements, neither Mirum nor its Affiliates (excluding any Acquirer or Acquirer Affiliates as provided in Section 3.6(b)) shall (either through its own efforts or with an Affiliate or Third Party) on a Licensed
Product-by-Licensed Product basis, (x) develop any Competing Product prior to the five (5) year anniversary of the First Commercial Sale of such Licensed Product or
(y) commercialize any Competing Product prior to the eight (8) year anniversary of the First Commercial Sale of such Licensed Product. As used herein, the following terms will have the following meaning: 

(i) “Competing Product” means any product that is or contains a compound (A) the primary method of action of
which is ASBT Inhibition Activity or (B) that is commercialized or developed for any PFIC Indication, ALGS Indication or Biliary Atresia Indication; provided, however, that foregoing clause (B) shall not apply with respect to (1) a
given Indication if a Product Failure has occurred with respect to such Indication (e.g., if a Product Failure has occurred for a Licensed Product for the Biliary Atresia Indication, Mirum may thereafter develop and commercialize a product for the
Biliary Atresia Indication if such product uses a different primary method of action than ASBT Inhibition Activity) or (2) a given product if such product is a Complementary Product. 

(ii) “Product Failure” means, with respect to a SHP625 Licensed Product for the PFIC Indication, ALGS Indication or
Biliary Artesia Indication that both (A) after using Commercially Reasonable Efforts in accordance with Section 5.6 and as required under the Sanofi Agreement, Satiogen Agreement and Pfizer Agreement, as applicable, Mirum determines in
good faith that further Development and Commercialization of Licensed Product is not commercially viable because of materially adverse pre-clinical or clinical pathology or toxicology data or clinical efficacy
data with respect to such Licensed Product and (B) no SHP625 Licensed Product was previously successfully Commercialized for such Indication. 

(iii) “Complementary Product” means a product for which the development and commercialization is not deleterious to
the sales or pricing of Licensed Products. 
 (b) In the event of a Change in Control of Mirum, the exclusivity provisions set forth
above shall [...***...] to the extent that such [...***...] is developing or commercializing (alone or with a Third Party) a Competing Product if, and only if (i) such [...***...] do not obtain rights or access (other than
access in connection with due diligence prior to the Change in Control transaction) to and do not use any Confidential Information of Shire, Shire Know-How, Pfizer
Know-How, Sanofi Know-How, Satiogen Know-How or Royalty Patents; (ii) the [...***...] development and
commercialization activities related to such Competing Product are kept separate from the Development and Commercialization activities for Compounds and Licensed Products 

  
 14 

 
under this Agreement; (iii) any personnel of Mirum or any of its Affiliates involved with Compounds or Licensed Products are not involved in any way with the Competing Products, (iv) Mirum
puts in place firewalls and other protections that are reasonably designed to ensure that the foregoing clauses (i), (ii) and (iii) are complied with, and (v) Mirum otherwise continues to meet its obligations under this Agreement. For the
purposes of this Agreement, “Change in Control” means (a) a sale of all or substantially all of the assets of Mirum to a Third Party; (b) any consolidation or merger of Mirum with or into any other corporation or other
entity or person, or any other corporate reorganization, in which the beneficial owners of the capital stock of Mirum immediately prior to such consolidation, merger or reorganization have (directly or indirectly) less than fifty percent (50%) of
the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation, merger or reorganization; or (c) any transaction or series of related transactions to which
Mirum is a party in which in excess of fifty percent (50%) of Mirum voting power (including the power to vote for Mirum’s board of directors) is transferred to a Third Party; provided that a change in control will not include (x) any
consolidation or merger effected exclusively to change the domicile of Mirum, or (y) any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by Mirum or any successor, or
indebtedness of Mirum is cancelled or converted, or a combination thereof. 
  

	4.	 COMPENSATION 

4.1 Upfront Payment. Within [...***...] after the Effective Date, Mirum shall pay Shire a
one-time, non-refundable, and non-creditable upfront cash payment of seven million five hundred thousand Dollars ($7,500,000)
(the “Upfront Payment”). 
 4.2 Equity Issuance. The Parties acknowledge and agree that, simultaneously with
the execution of this Agreement, the Parties are entering into that certain Common Stock Issuance Agreement and certain additional agreements referenced therein (collectively, the “Investment Agreements”) with respect to an issuance
of Common Stock by Mirum to Shire (or its Affiliate) in Mirum, in partial consideration for the rights granted under this Agreement to Mirum. Shire and Mirum further agree and acknowledge that Mirum’s entering into, and performance of, this
Agreement is an essential factor for Shire entering into the Investment Agreements, without which Shire would not have entered into the Investment Agreements. 

4.3 Development Milestone Payments. 

(a) SHP625 Licensed Product. Mirum shall make the following non refundable and
non-creditable development milestone payments to Shire within [...***...] after the first achievement of each applicable milestone for an Indication covered by each section of the table below for a
Licensed Product containing the SHP625 Compound, either alone or in combination with other agents (a “SHP625 Licensed Product”), by Mirum or any of its Affiliates or any of their respective sublicensees. Each such milestone payment
shall be paid only once for each such Indication for an SHP625 Licensed Product during the Term, the first time an SHP625 Licensed Product reaches such milestone event, regardless of the number of times such milestone is reached by an SHP625
Licensed Product for the same Indication. For clarity, (i) the milestone payments in each section of the table below are paid once for an Indication covered by such section of the table but, in the case of section 4 of the table below only, may
be paid multiple times if 

  
 15 

 
multiple Other Indications are covered by such section of the table, (ii) if the same SHP625 Licensed Product is Developed for more than one Indication, the applicable development milestones
will apply for each such Indication and (iii) if a disease or condition listed under the header “INDICATIONS AND USAGE” covers more than one of the PFIC Indication, ALGS Indication, Biliary Atresia Indication or Other
Indication based on clinical data in such disease, condition or Indication, then the applicable milestone payments in the table below shall apply for each such Indication when the applicable milestone event is reached (e.g., if achievement of a
milestone event is based on Regulatory Approval for “treatment of pruritus in pediatric cholestatic liver disease” which is supported by studies of PFIC patients, ALGS patients, and Biliary Atresia patients (as evidenced by Regulatory
Materials), then the milestone payments for the PFIC Indication, ALGS Indication, and Biliary Atresia shall all apply when the applicable milestone event is reached). 

  
 16 

					
	 Milestone Event
	  	Milestone Payment	 
	 1. PFIC Indication:
	  			
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 2. ALGS Indication:
	  			
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 3. Biliary Atresia Indication:
	  			
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 4. Each and Every Other Indication:
	  			
	 [...***...]
	  	$	[...***...]	 

 (b) SHP626 Licensed Product. Mirum shall make the following
non-refundable and non-creditable development milestone payments to Shire within [...***...] after the first achievement of each applicable milestone for a
Licensed Product containing the SHP626 Compound, either alone or in combination with other agents (a “SHP626 Licensed Product”), by Mirum or any of its Affiliates or any of their respective sublicensees. Each such milestone payment
shall be paid only once for the first Indication for which an SHP626 Licensed Product is developed during the Term, the first time such SHP626 Licensed Product reaches such milestone event, regardless of the number of SHP626 Licensed Products or the
number of Indications for which SHP626 Licensed Products are developed. 
  

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 

  
 17 

 (c) Determination that Milestone Events Have Occurred. Mirum shall notify
Shire promptly of the achievement of each development milestone event under Section 4.3(a) and 4.3(b). If, notwithstanding the fact that Mirum has not provided Shire such a notice, Shire believes that any such milestone event has been achieved,
it may so notify Mirum in writing and the Parties shall promptly meet and discuss in good faith whether such milestone event has been achieved. Any dispute under this Section 4.3(c) regarding whether or not a milestone event has been achieved
shall be subject to resolution in accordance with Section 11.3. If, at the time a milestone event is accomplished by Mirum or any of its Affiliates or any of their respective sublicensees, any prior milestone event(s) have not been accomplished
and the milestone payments for such prior milestone event(s) have not been paid for a given Licensed Product and given country or jurisdiction (and, in the case of SBP625 Licensed Product, a given Indication), as applicable, the milestone payment(s)
for such prior milestone event(s) shall then also be due and payable within [...***...]. 
 4.4 Sales Milestone Payments.
Mirum shall make the following one-time, non refundable and non-creditable sales milestone payments to Shire when the aggregate Net Sales of all Licensed Products in the
Territory in a given calendar year first reach the thresholds specified below. Mirum shall notify Shire promptly of the achievement of each such sales threshold. Each sales milestone payment shall be made by Mirum within [...***...] after the
end of the calendar quarter in which such sales threshold is achieved. If more than one sales threshold is reached in any given calendar year, then Mirum shall pay Shire a separate milestone payment for each such threshold that is reached. 

 

					
	 Threshold for Aggregate
Worldwide Net Sales in a Calendar
Year
	  	Milestone Payment	 
	 $[...***...]
	  	$	[...***...]	 
	 $[...***...]
	  	$	[...***...]	 
	 $[...***...]
	  	$	[...***...]	 

 4.5 Royalty Payments. 

(a) Royalty Rates. Subject to the terms of this Section 4.5, Mirum shall pay to Shire
non-refundable, non-creditable royalties on Net Sales of all Licensed Products in the Territory during the Royalty Term, calculated by multiplying the applicable portion
of aggregate Net Sales of all Licensed Products in the Territory in a calendar year by the corresponding royalty rates in the table below and aggregating the resulting amounts; provided that, if any of such Licensed Products are neither SBP625
Licensed Products nor SBP626 Licensed Products (such Licensed Products, “Other Licensed Products”), Mirum shall only be required to pay to Shire [...***...] of the royalties that would otherwise be due for such Other Licensed
Products pursuant to this Section 4.5: 
  

			
	 Net Sales of All Licensed Product
	  	Royalty Rate
	 For that portion of aggregate Net Sales of all Licensed Products during a calendar year less
than or equal to $[...***...]
	  	[...***...]%
	 For that portion of aggregate Net Sales of all Licensed Products during a calendar year greater
than $[...***...] and less than or equal to $[...***...]
	  	[...***...]%
	 For that portion of aggregate Net Sales of all Licensed Products during a calendar year greater
than $[...***...]
	  	[...***...]%

  
 18 

 (b) Royalty Term. Royalties under this Section 4.5 with respect to a
particular Licensed Product and country will commence on the First Commercial Sale of such Licensed Product in such country and shall continue until the later of (i) the expiration of the last-to-expire Valid Claim of the Royalty Patents in such country where, but for the license grants and assignment hereunder, such Licensed Product or the Compound contained therein or such Licensed
Product’s or Compound’s manufacture or use would infringe such Valid Claim, (ii) expiration of any Regulatory Exclusivity for the Licensed Product in such country and (iii) the tenth (10th) anniversary of the First Commercial
Sale of such Licensed Product in such country (the “Royalty Term”). 
 (c) Royalty Reports and Payments.
Within [...***...] following the end of each calendar quarter following the First Commercial Sale of a Licensed Product anywhere in the Territory, Mirum shall provide Shire with a report containing the following information for the applicable
calendar quarter, on a Licensed Product-by-Licensed Product and country-by-country basis:
(i) the amount of gross sales of such Licensed Product in such country, (ii) an itemized calculation of Net Sales in such country showing deductions provided for in the definition of Net Sales in Section 1.37, (iii) a calculation of
the royalty payment due on such sales, (iv) an accounting of the number of units and prices for Licensed Product sold, (v) the exchange rate for such country (pursuant to Section 4.6), (vi) the date of First Commercial Sale of such
Licensed Product in such country, and (vii) identification of whether such Licensed Product is an SHP625 Licensed Product or an SHP626 Licensed Product. Concurrent with the delivery of the applicable quarterly report, Mirum shall pay all
amounts due to Shire pursuant to this Section 4.5 with respect to Net Sales by Mirum, any of its Affiliates and their respective sublicensees for such calendar quarter. 

(d) Royalty Adjustment 

(i) Royalty Adjustments for Payments under Sanofi Agreement for SHP626 Licensed Products. To the extent such amounts are
required to be paid to Sanofi in such calendar quarter for SHP626 Licensed Products pursuant to the Sanofi Agreement (as it exists as of the Effective Date) and such amounts are actually paid by Mirum to Sanofi, the royalty payment that would
otherwise be due with respect to any SHP626 Licensed Product in any calendar quarter pursuant to Section 4.5(a) shall be reduced, on calendar quarter-by-calendar
quarter basis, by an amount equal to (A) [...***...] ([...***...] if the Compound Manufacturing Option is exercised under the Sanofi Agreement) of that portion of annual Net Sales less than $[...***...] plus (B) [...***...]
([...***...] if the Compound Manufacturing Option is exercised under the Sanofi Agreement) of that portion of annual Net Sales greater than or equal to $[...***...]. 

  
 19 

 (ii) Royalty Adjustments for Payments under Satiogen Agreement for Licensed
Products. To the extent such amounts are required to be paid to Satiogen in such calendar quarter for Licensed Products pursuant to the Satiogen Agreement (as it exists as of the Effective Date) and such amounts are actually paid by Mirum to
Satiogen, the royalty payment that would otherwise be due with respect to any Licensed Product in any calendar quarter pursuant to Section 4.5(a) shall be reduced, on calendar
quarter-by-calendar quarter basis, by an amount equal to [...***...] of Net Sales. 

(iii) Royalty Adjustments for Third Party Intellectual Property. If it is necessary for Mirum or its Affiliates or their
respective sublicensees to obtain a license from any Third Party (each a “Third Party License” which, for clarity, expressly exclude any Assigned Agreements) under any Valid Claim owned or controlled by such Third Party directed to
a Compound (excluding formulation), or its manufacture (if no non-infringing manufacturing alternative is available) or method of use of a Compound (a “Third Party Claim”) in order to avoid
the infringement or misappropriation of such Third Party Claim by the manufacture, use or sale of a Licensed Product, then the royalty payment that would otherwise be due in any calendar quarter pursuant to Section 4.5(a) shall be reduced, on a
Licensed Product-by-Licensed Product and calendar quarter-by-calendar quarter basis, by
(A) [...***...] of any royalty amount paid by Mirum or its Affiliates in such calendar quarter to such Third Party in consideration for such Third Party License for such Licensed Product, or (B) [...***...] of the difference (if any)
between (x) the calendar quarter royalty payment due to Mirum pursuant to its sublicense agreement with such sublicensee for such Licensed Product and (y) the calendar quarter royalty payment that would otherwise be due to Mirum for such
Licensed Product pursuant to such sublicense agreement in the absence of such Third Party License, in the event such Third Party License is obtained by a sublicensee of Mirum hereunder and such sublicensee is entitled [...***...]. If any such
Third Party License includes a license under a Third Party Claim as well as other intellectual property rights that are not Third Party Claims, then the calendar quarter royalty payment that would otherwise be due pursuant to Section 4.5(a)
shall be reduced by up to [...***...] of that portion of the total royalty amount payable by Mirum or its Affiliates or its sublicensee, as applicable, in such calendar quarter to such Third Party in consideration for such Third Party License
that the Parties agree is a reasonable royalty for a license under only the applicable Third Party Claim(s). 
 (iv) Royalty
Adjustment for Generic Entry. On a Licensed Product-by-Licensed Product and
country-by-country basis, if, in any calendar quarter during the Royalty Term following First Commercial Sale in a country and the first commercial sale of a Generic
Product in a country (“Generic Entry”) (A) there is no Valid Claim within the Royalty Patents in such country, (B) there is no Regulatory Exclusivity for such Licensed Product in such country and (C) the market share of
Mirum and its Affiliates or their respective sublicensees, as applicable, for such Licensed Product in the Field in such country in such calendar quarter (as measured in Dollars or local currency by reputable published data for such country, e.g. by
reference to market share data collected by IMS) (“Market Share”) is (1) reduced by greater than [...***...] but less than [...***...] compared to the Market Share in the immediately preceding calendar quarter, then
the applicable royalty payable to Shire under Section 4.5(a) (after adjustment by virtue of Section 4.5(d)(i) in the case of any SHP626 Licensed Product and Section 4.5(d)(ii) in the case of any Licensed Products) shall be reduced by
[...***...], (2) reduced by equal to or greater than [...***...] but less than [...***...] compared to the Market Share in the immediately preceding calendar quarter, then 

  
 20 

 
the applicable royalty payable to Shire under Section 4.5(a) (after adjustment by virtue of Section 4.5(d)(i) in the case of any SHP626 Licensed Product and Section 4.5(d)(ii) in
the case of any Licensed Products) shall be reduced by [...***...] or (3) reduced by equal to or greater than [...***...] compared to the Market Share in the immediately preceding calendar quarter, then the applicable royalty
payable to Shire under Section 4.5(a) shall be reduced to [...***...], with, in each case (1), (2), and (3), such reduction applying in any following quarter. Notwithstanding the foregoing, the royalty adjustment set forth in this
Section 4.5(d)(iv) shall not apply in the event of any reduction in the Market Share of any sublicensee of Mirum hereunder, unless such reduction in such sublicensee’s Market Share triggers an equivalent adjustment of royalties payable by
such sublicensee to Mirum pursuant to the applicable sublicense agreement. 
 (v) Limitations. Notwithstanding the foregoing,
(A) in no event shall the royalty payment that would otherwise be due to Shire pursuant to Section 4.5(a) with respect to a particular calendar quarter be reduced below [...***...] by virtue of Section 4.5(d)(i) and 4.5(d)(ii)
and (B) in no event shall the royalty payment that would otherwise be due to Shire pursuant to Section 4.5(a) with respect to a particular calendar quarter, after adjustment by virtue of Section 4.5(d)(i) and 4.5(d)(ii), be reduced by
more than [...***...] by operation of Section 4.5(d)(iii) or Section 4.5(d)(iv) subclauses (1) or (2). 
 4.6
Payment Method. All payments due under this Agreement to Shire shall be made by bank wire transfer of Dollars in immediately available funds to an account designated by Shire. With respect to sales of Licensed Products invoiced in a currency
other than Dollars, all amounts reported and payable under this Agreement shall be calculated based on the domestic currency where such sale is made and converted (as applicable) into the Dollar equivalent. The Dollar equivalent shall be calculated
using the average of the daily foreign exchange rate (local currency per one Dollar) published in The Wall Street Journal, Eastern Edition, under the heading “Currency Trading” on the last business day of each month during the
applicable calendar quarter, or for periods less than a calendar quarter, the average of the daily rates published in The Wall Street Journal for such period. 

4.7 Late Payment. If Mirum fails to make any payment due to Shire under this Agreement, then interest shall accrue on a monthly
basis at the rate equal to [...***...] above the then-applicable prime rate as published in The Wall Street Journal, Eastern Edition, or at the maximum rate permitted by applicable Law, whichever is lower. 

4.8 Records; Inspection. Mirum shall, and shall ensure that its Affiliates and their respective sublicensees will, keep complete,
true and accurate books of account and records for the purpose of determining the payments to be made under this Agreement, including the calculation of Net Sales of the Licensed Products. Such books and records shall be kept for at least
[...***...] following the end of the calendar year to which they pertain and shall be kept in accordance with GAAP and Mirum’s internal practices and procedures, consistently applied. Such records shall be open for inspection during such
period by independent certified public accountants selected by Shire, solely for the purpose of verifying payment statements hereunder. Such inspections shall be made no more than [...***...] each calendar year, on reasonable notice during
normal business hours. Any unpaid amounts (plus interest as set forth in Section 4.7) that are discovered shall be paid promptly by Mirum. Inspections conducted under this Section 4.8 shall be at the expense of Shire, unless the inspection
discloses an underpayment by Mirum of [...***...] or more of the amount due for any period covered by the inspection, whereupon all costs relating to the inspection for such period shall be paid promptly by Mirum. 

  
 21 

 4.9 Taxes. 

(a) Taxes. Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or
indirectly from the efforts of the Parties under this Agreement. For clarity, all payments to be made under this Agreement shall be made plus value added tax, if applicable. 

(b) VAT. 

(i) All payments or amounts due under this Agreement, whether monetary or non-monetary are
exclusive of VAT and Sales Tax and their equivalents. Any party receiving a supply under this agreement, hereby covenants that it will pay any such VAT and Sales Tax correctly charged in addition to any amounts due under this agreement. Where the
prevailing legislation requires a VAT or Sales Tax reverse charge, then the receiving Party covenants that it shall correctly account for VAT and Sales Tax in respect of the services received. The supplying party agrees that it will raise a tax
invoice (or equivalent document) to support the charge to VAT and Sales Tax. 
 (ii) For the purposes of VAT, the services, rights
and licenses provided by Shire under this Agreement shall be considered to be taxed under by Art 44 of Council Directive 2006/112/EC or any equivalent provision in the country of performance if performed outside the European Union and as such will
be considered to be taxed for VAT and Sales Taxes purposes in the country of the recipient. For the purposes of this clause, Mirum warrants that it is established in the United States for the purposes of receiving any such services, rights or
licenses. 
 (iii) Any supply of goods under this agreement shall be taxed in accordance with the prevailing VAT and Sales Tax
legislation. All parties agree that they will reasonably cooperate to ensure the use of any VAT and Sales Tax exemptions, suspensions or other reliefs. 

(iv) Subject to any other provision in this agreement, any goods supplied will be shipped under Incoterms 2010 – EXW (Shire
facility) with receiving Party acting as the importer. 
 (v) Each Party shall be responsible for any penalties or interest accruing
due to incorrect VAT or Sales Tax treatment of the supplies of goods or services made by that Party or any failure to correctly account for VAT or Sales Taxes on any receipt of a supply of goods or services under this agreement except where those
penalties or interest arise as a result of the actions of the other party, in which case that party shall be liable to reimburse the value of the penalties and interest. 

  
 22 

 (vi) If an invoice is raised that is subject to VAT or Sales Tax but is raised in a
currency other than the local currency of the country from which the tax is being charged, the invoice must additionally display this tax in the local currency of the country concerned in accordance with the prevailing tax invoicing requirements,
having been converted using the relevant exchange rate published on Bloomberg or such other tax authority-approved service applicable at the invoice date. 

(c) Tax Cooperation. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax
withholding or similar obligations in respect of royalties, milestone payments, and other payments made by Mirum to Shire under this Agreement. To the extent Mirum is required to deduct and withhold taxes on any payment to Shire, Mirum shall pay the
amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Shire an official tax certificate or other evidence of such withholding sufficient to enable Shire to claim such payment of taxes. Each Party
shall provide the other with reasonable assistance to enable the recovery, as permitted by applicable Laws, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for
the benefit of the Party bearing such withholding tax or value added tax. Mirum shall require its sublicensees to cooperate with Shire in a manner consistent with this Section 4.9(b). 

(d) Taxes Resulting from Mirum Action. If Mirum is required to make a payment to Shire that is subject to a deduction or
withholding of tax, then (i) if such withholding or deduction obligation arises as a result of any action by Mirum, including any assignment or sublicense, or any failure on the part of Mirum or its Affiliate to comply with applicable Laws or
filing or record retention requirements, that has the effect of modifying the tax treatment of the Parties hereto (a “Mirum Withholding Tax Action”), then the sum payable by Mirum (in respect of which such deduction or withholding
is required to be made) shall be increased to the extent necessary to ensure that Shire receives a sum equal to the sum that it would have received had no such Mirum Withholding Tax Action occurred, and (ii) otherwise, the sum payable by Mirum
(in respect of which such deduction or withholding is required to be made) shall be made to Shire after deduction of the amount required to be so deducted or withheld, which deducted or withheld amount shall be remitted to the proper Governmental
Authority in accordance with applicable Laws. 
  

	5.	 DEVELOPMENT AND COMMERCIALIZATION 

5.1 Alliance Managers. Within [...***...] after the Effective Date, each Party shall appoint and notify the other Party of
the identity of a representative having the appropriate qualifications, including a general understanding of pharmaceutical development and commercialization issues, to act as its alliance manager under this Agreement (the “Alliance
Manager”). The Alliance Managers shall serve as the primary contact points between the Parties for the purpose of providing Shire with information on the progress of Mirum’s Development and Commercialization activities under this
Agreement. The Alliance Managers shall also be primarily responsible for facilitating the flow and timely coordination of information, publications (including press releases) and reports from Mirum (including Development reports, Commercialization
reports, and royalty reports) and communication, coordination and collaboration between the Parties, including activities related to the Existing Trials prior to their transition to Mirum. Each Party may replace its Alliance Manager at any time upon
written notice to the other Party. 

  
 23 

 5.2 Development 

(a) Development Responsibilities. As between the Parties, Mirum, at its sole cost and expense, shall have sole authority and
responsibility for conducting or having conducted Development activities with respect to Compounds and Licensed Products in the Territory, in accordance with the terms and conditions of this Agreement. Mirum, its Affiliates and their respective
sublicensees shall conduct all such activities in accordance with the Development Plan and in compliance with all applicable Laws. 

(b) Development Plan. Mirum shall prepare an [...***...] written development plan, which shall specify the Compound and
Licensed Product Development activities to be conducted by Mirum, its Affiliates, and their respective sublicensees and subcontractors, and the timeline regarding such activities (collectively, as updated and amended, the “Development
Plan”). The initial Development Plan is attached to this Agreement as Exhibit 5.2(b). Beginning with the first full calendar year following the Effective Date, on an [...***...] basis (no later than [...***...]), Mirum
shall review and, as required, prepare an update and amendment to the then-current Development Plan and send such updated and amended Development Plan to Shire for review and comment by Shire (which comments Mirum shall consider in good faith);
provided that (a) any such update and amendment shall be consistent with Mirum’s diligence obligations set forth in Section 5.6 and, unless terminated, the Assigned License Agreements. Such updated and amended Development Plan shall
reflect any changes with respect to the Development of Licensed Products. 
 (c) Development Records and Reports. Mirum shall
maintain complete and accurate records (in the form of technical notebooks or electronic files where appropriate) of all Development activities conducted by it or its Affiliates or their respective sublicensees, as applicable, under this Agreement
and all Information resulting from such work. Such records, including any electronic files where such Information may also be contained, shall fully and properly reflect all work done and results achieved in the performance of the Development
activities in sufficient detail and in good scientific manner appropriate for applicable patent and regulatory purposes. [...***...] prior to the expiry of each consecutive [...***...] period during the Term, Mirum shall provide Shire
with a written report summarizing its Development activities conducted by Mirum or its Affiliates or their respective sublicensees, as applicable, under this Agreement and the results of such activities. Any information or report provided by Mirum
to Shire pursuant to this Section 5.2(c) shall be deemed to be Mirum’s Confidential Information and subject to the provisions of Article 7. 

(d) Know-How and Material Transfer; Transition Services. 

(i) To the extent feasible as of the Effective Date, at no additional cost to Mirum, Shire shall deliver, or cause its Affiliates to
deliver, to Mirum the items set forth on Exhibit 5.2(d) in accordance with the schedule set forth on Exhibit 5.2(d). 
 (ii)
In addition, as soon as practicable after the Effective Date, the Parties shall negotiate in good faith and enter into a transition services agreement (“Transition Services Agreement”) that (1) sets forth the activities to be
conducted by Shire and Mirum to transfer the Development of Compound and Product from Shire to Mirum, (2) sets forth the 

  
 24 

 
process and timelines for Shire’s delivery to Mirum of copies of the clinical- and manufacturing-related Shire Know-How, Pfizer Know-How, Sanofi Know-How and Satiogen Know-How (to the extent not previously delivered to Mirum pursuant to Section 5.2(d)(i)) in
such written or electronic format as it is held by Shire or its Affiliate (3) sets forth the quantities of Compound and Licensed Product materials and intermediates in the possession of Shire or any of its Affiliates to be transferred to Mirum
at no additional cost to Mirum (which quantities shall exclude any such materials Shire expects to be required for the Existing Trials and other activities of Shire to be conducted prior to the full transition of activities to Mirum hereunder) and
(4) may provide for the assignment from Shire (or its Affiliates) to Mirum of certain other agreements related to the Development of Compound and Product. Mirum shall be responsible for the costs of such transition services and for Shire’s
costs (including fees) for such quantities of Compound and Licensed Product as further set forth in the Transition Services Agreement. Pending the execution of the Transition Services Agreement and full transition of activities to Mirum hereunder
and provided that Mirum is negotiating to enter into the Transition Services Agreement in good faith, Shire and its Affiliates will continue to conduct the Existing Trials, pharmacovigilance, manufacturing, storage and other activities relating to
Compounds and Licensed Products in the ordinary course of business. Other than with respect to Existing Trials (for which costs are governed by Section 5.3(b)), Mirum shall reimburse Shire within [...***...] of invoicing for all
reasonable internal and out-of-pocket costs incurred by Shire or its Affiliates for the conduct of such activities from the Effective Date until such transition is
complete (and, in the case of CMC and toxicology activities, all such costs incurred on or after [...***...] until such transition is complete). 

(iii) EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, ANY MATERIALS SUPPLIED BY SHIRE UNDER THIS SECTION 5.2(d) OR THE TRANSITION
SERVICES AGREEMENT ARE SUPPLIED “AS IS” AND SHIRE MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR
THAT THE USE OF THE MATERIALS DOES NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS OF A THIRD PARTY. Mirum assumes all liability for damages which may arise from its use, storage or disposal of such materials. Shire will
not be liable to Mirum for any loss, claim or demand made by Mirum or its Affiliates, or made against Mirum or its Affiliates by any Third Party, due to or arising from the use of such materials. 

5.3 Regulatory Matters. 

(a) Subject to any restrictions in the Assigned License Agreements to the extent of Information under the applicable Assigned License
Agreement, promptly following the Effective Date, Shire shall provide to Mirum copies of all Regulatory Materials in Shire’s or its Affiliates’ possession within the Shire Know-How, Pfizer Know-How, Sanofi Know-How and Satiogen Know-How and the Parties will take all such actions (including execution of such documents) as
reasonably necessary to transfer rights and responsibilities with respect to all filings within such Regulatory Materials to Mirum in accordance with a mutually agreed timeline, including transfer of investigational new drug applications for the
Existing Trials to Mirum as soon as possible after the Effective Date. Except in connection with the Existing 

  
 25 

 
Trials conducted by or on behalf of Shire or its Affiliates prior to the transition to Mirum as set forth in Section 5.3(b), Mirum shall have sole responsibility and control, at its sole
cost and expense, for seeking, preparing, obtaining, and maintaining all filings with Regulatory Authorities to Develop and manufacture the Licensed Products within the Territory and all Regulatory Approvals to Commercialize the Licensed Products
within the Territory, and conducting all communications related thereto with the Regulatory Authorities in the Territory. 
 (b) The
Parties shall work in good faith to transition the conduct of the clinical trials listed on Exhibit 5.3(b) (“Existing Trials”) from Shire (or its Affiliate) to Mirum as soon as practicable after the Effective Date. Until such
transition is complete, (a) Mirum hereby grants to Shire a license under any Regulatory Materials, Patents and Information Controlled by Mirum to the extent necessary for Shire (or its Affiliate) to conduct the Existing Trials and
(b) Mirum shall reimburse Shire within [...***...] of invoicing for all reasonable internal and out-of-pocket costs incurred by Shire or its Affiliates for
the conduct of the Existing Trial from the Effective Date until such transition is complete. Mirum shall use Commercially Reasonable Efforts to effectuate the transition of the Existing Trials to Mirum including, if needed, using Commercially
Reasonable Efforts to enter into agreements with Third Parties previously working with Shire or its Affiliates in connection with the Existing Trials. 

(c) Mirum shall notify Shire promptly following its determination that any event, incident, or circumstance has occurred that would
result in the need for a recall, market suspension, or market withdrawal of Compounds or Licensed Products in the Territory. Mirum shall have the right to make the final determination whether to voluntarily implement any such recall, market
suspension, or market withdrawal in the Territory. Mirum shall conduct any recall, market suspension, or market withdrawal of Compounds or Licensed Products in the Territory in compliance with applicable Law. Mirum shall have the sole responsibility
and control over all recalls, market suspensions, or market withdrawals of Compounds or Licensed Products in the Territory at its own expense. 

(d) Any information provided by Mirum to Shire pursuant to this Section 5.3(c) shall be deemed to be Mirum’s Confidential
Information and subject to the provisions of “Article 7. 
 5.4 Manufacturing. As between the Parties, Mirum shall
have the sole responsibility and control, at its sole cost and expense, over the Manufacturing of Compounds and Licensed Products, including performing CMC Activities with respect to Compound. 

5.5 Commercialization 

(a) Commercialization Responsibilities. As between the Parties, Mirum shall have the sole responsibility and control over
conducting or having conducted Commercialization activities with respect to Licensed Products in the Territory, at its sole cost and expense, in accordance with the terms and conditions of this Agreement. Mirum shall conduct all such activities in
compliance with all applicable Laws. It is understood that as between the Parties, Mirum shall be solely responsible, at its sole cost and expense, for handling all detailing, distribution, order processing, invoicing and collection, receivables,
and returns for Licensed Products in the Territory. 

  
 26 

 (b) Trademarks. Mirum shall have the right to brand Licensed Products using
Mirum related trademarks and any other trademarks and trade names it determines appropriate for the Licensed Products which may vary by country or within a country (“Product Marks”), provided that Mirum shall not, and shall not
permit its Affiliates or their respective sublicensees or subcontractors to, make any use of the trademarks or house marks of Shire or its Affiliates (including their corporate names) or any trademark confusingly similar thereto. As between the
Parties, Mirum or its Affiliate or their respective sublicensees or subcontractors (as applicable) shall own all rights in the Product Marks and shall register and maintain the Product Marks in the countries and regions it determines reasonably
necessary at its own cost and expense. 
 (c) Standards of Conduct. Mirum shall, and shall ensure that its Affiliates and their
respective sublicensees and subcontractors have the written obligation to, comply with all applicable Laws concerning the advertising, marking, sales, and marketing of prescription drug products in Commercializing Licensed Products in the Territory
under this Agreement, including the Foreign Corrupt Practices Act of 1977, as amended (“FCPA”) and any other applicable anti-bribery laws. Mirum shall, during the Term, promptly notify Shire in writing with respect to any material non-compliance (other than non-compliance of the FCPA which shall be without regard to materiality) regarding the Commercialization of Licensed Products of which it becomes
aware. 
 (d) Commercialization Reports. Mirum shall, on an [...***...], no later than [...***...] of
[...***...], provide Shire with a reasonably detailed report of its and its Affiliate’s and their respective sublicensee’s and subcontractor’s (as applicable) Commercialization activities with respect to Licensed Products in the
Major Markets in the immediately preceding [...***...]. Any information or report provided by Mirum to Shire pursuant to this Section 5.5 shall be deemed to be Mirum’s Confidential Information and subject to the provisions of Article
7. 
 5.6 Diligence. 

(a) During the Term, Mirum (by itself or through its Affiliates or sublicensees, as applicable) shall, at its sole cost and expense, use
Commercially Reasonable Efforts to (i) [...***...], and [...***...] in [...***...] and [...***...], (ii) [...***...], (iii) [...***...] and (iv) [...***...]. 

(b) For clarity, it is understood and acknowledged that to the extent that Mirum (by itself or through its Affiliates or sublicensees,
as applicable) uses Commercially Reasonable Efforts to [...***...], Mirum shall be in compliance with Section 5.6(a) with respect to [...***...]. 
  

	6.	 INTELLECTUAL PROPERTY 

6.1 Ownership of Arising IP. As between the Parties, Mirum or its Affiliate or their respective sublicensees or subcontractors,
as applicable, shall solely own all Information, discoveries, works and inventions (patentable or not) invented, created, discovered, generated, authored, conceived, or reduced to practice solely by or on behalf of Mirum or its Affiliates or their
respective sublicensees or subcontractors under this Agreement using Shire IP or Shire Confidential Information, including Patents filed thereon and other intellectual property rights therein and registrations thereon (collectively “Arising
IP” and any Patents thereon, “Arising Patents”). 

  
 27 

 6.2 Patent Prosecution. 

(a) Shire Patents. All decisions and actions with respect to the preparation, filing, prosecution and maintenance of the Shire
Patents shall be the responsibility of Mirum, using patent counsel reasonably acceptable to Shire, at Mirum’s sole cost and expense; provided that (i) Mirum shall keep Shire reasonably informed regarding the preparation, filing,
prosecution, and maintenance of the Shire Patents and (ii) Mirum shall not abandon or discontinue the prosecution or maintenance of any Shire Patent in a country without notifying Shire in writing at least [...***...] in advance of the
due date of any payment or other action that is required to prosecute and maintain such Shire Patent, and, upon such notice, all licenses under such Patent granted in Section 3.1 shall terminate upon delivery of such notice and Shire shall have
the option, but not the obligation, to prepare, file, prosecute and maintain (including with respect to related interference, re-issuance, re-examination and opposition
proceedings) such Shire Patent in the Territory at its sole cost and expense. 
 (b) Arising Patents, Sanofi Patents, and Satiogen
Patents. As between the Parties, all decisions and actions with respect to the preparation, filing, prosecution and maintenance of the Arising Patents, Sanofi Patents and Satiogen Patents shall be the responsibility of Mirum, at Mirum’s
sole cost and expense; provided that Mirum shall keep Shire reasonably informed regarding the preparation, filing, prosecution, and maintenance of such Patents. 

(c) Patent Term Extensions. As between the Parties, Mirum shall have the authority and responsibility to file for and seek to
obtain patent term extensions (including any pediatric exclusivity extensions as may be available) or supplemental protection certificates or their equivalents in any country with respect to Shire Patents covering Compound or Licensed Products. 

(d) Data Exclusivity. With respect to data exclusivity periods, Mirum shall have the sole right, but not the obligation
(consistent with its obligations under applicable Laws (including any applicable consent order)), to seek, maintain, and enforce all such data exclusivity periods available for Licensed Products. 

(e) Cooperation. Promptly following the Effective Date (but no less than [...***...] before any statutory bar date), Shire
will provide to Mirum documents as necessary to prosecute and maintain the Shire Patents and Sanofi Patents. Shire shall cooperate with Mirum and shall execute any power of attorney or similar document, in each case to the extent reasonably required
to allow Mirum to assume the preparation, filing, prosecution, and maintenance of the Shire Patents in the name of Shire or its designated Affiliate. Mirum shall cooperate with Shire, in each case to the extent reasonably required to allow Shire or
its designated Affiliate to assume the preparation, filing, prosecution, and maintenance, of any Shire Patent abandoned by Mirum pursuant to Section 6.2(a). 

  
 28 

 6.3 Patent Enforcement. 

(a) Notification. If either Party becomes aware of any existing or threatened infringement of the Shire Patents in the Territory,
which infringing activity involves the manufacture, use, import, offer for sale, or sale of any Compound or Licensed Product in the Territory (a “Product Infringement”), it shall promptly notify the other Party in writing to that
effect, and the Parties will consult with each other regarding any actions to be taken with respect to such Product Infringement. 

(b) Right to Enforce. Mirum shall have the first right, but shall not be obligated, to bring an infringement action against any
person or entity engaged in a Product Infringement, at Mirum’s sole cost and expense. If Mirum fails to bring such an action with respect to a Shire Patent (or to settle or otherwise secure the abatement of such Product Infringement) prior to
the earlier of: (i) [...***...] following Mirum’s receipt or delivery of the notice under Section 6.3(a), or (ii) [...***...] before the deadline, if any, set forth in the applicable Laws for the filing of such actions, Shire
shall have the right to bring and control any such action, at its own expense and by counsel of its own choice. If Mirum becomes aware of, or receives notice, of any existing or threatened infringement of the Shire Patents in the Territory through a
notice under 21 U.S.C. 355(b)(3) or 21 U.S.C. 355(j)(2) (including a notice of a certification under 21 U.S.C. 355(b)(2)(A)(iv) or 21 U.S.C. 355(j)(2)(A)(vii)(IV)), Mirum will provide written notice to Shire within [...***...] of the date of
its receipt of such notice of whether Mirum will bring an infringement action against any person or entity engaged in such infringement of the Shire Patents within the period prescribed in 21 U.S.C. 355(c)(3)(C) or 21 U.S.C. 355(j)(5)(B),
respectively, at Mirum’s sole cost and expense. If Mirum elects not to bring such infringement action or does not provide the notice to Shire within such [...***...] period, Shire shall have the right to bring and control any such action,
at its own expense and by counsel of its own choice. 
 (c) Cooperation. If Mirum or Shire exercises its rights to enforce
Shire Patents pursuant to Section 6.3(b), each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including joining such action as a party plaintiff if
required by applicable Laws to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts; shall reasonably consider the other Party’s comments on any such
efforts. The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense; provided that (i) if Shire is required to join as a party,
Mirum shall reimburse Shire for its reasonable out-of-pocket expenses for such separate representation and (ii) the
non-enforcing Party shall at all times cooperate with the enforcing Party. Neither Party shall have the right to settle any patent infringement litigation under this Section 6.3 in a manner that diminishes the
rights or interests of the other Party without the prior written consent of such other Party, such consent not to be unreasonably withheld or delayed. 

(d) Expenses and Recoveries. The enforcing Party bringing a claim, suit or action under Section 6.3(b) shall be solely
responsible for any expenses incurred by such Party as a result of such claim, suit or action. If such Party recovers monetary damages in such claim, suit or action, such recovery shall be allocated first to the reimbursement of any out-of-pocket expenses incurred by the Parties in such litigation and any remaining amounts shall be shared as follows: (i) if Shire is the enforcing Party, the remaining
amount will be shared [...***...] to Shire and [...***...] to Mirum or (ii) if Mirum is the enforcing Party, the remaining amount will be retained by Mirum and treated as [...***...]. 

  
 29 

 (e) Arising Patents. Mirum shall have the sole right, but shall not be
obligated, to bring an infringement action against any person or entity engaged in any existing or threatened infringement of the Arising Patents, at Mirum’s sole cost and expense, and retain all monetary damages recovered in such claim, suit
or action. 
 6.4 Patent Oppositions and Other Proceedings. 

(a) If a Shire Patent becomes the subject of any proceeding commenced by a Third Party in connection with an opposition, action for
declaratory judgment, nullity action, interference, post-grant review, or other attack upon the validity, title or enforceability thereof, then Mirum shall have the first right, but not the obligation, to control such defense at its own expense
using counsel of its own choice. If Mirum decides that it does not wish to defend against such action, it shall notify Shire, reasonably in advance of all applicable deadlines, and Shire shall thereafter have the right, but not the obligation, to
assume defense of such action at its own expense. 
 (b) If Mirum or Shire exercises its rights to control the defense of a Shire
Patent pursuant to Section 6.4(a), the Party controlling any defense under this Section 6.4(b) shall permit the non-controlling Party to participate in the proceedings to the extent permissible under
applicable Laws and to be represented by its own counsel at the non-controlling Party’s expense. Notwithstanding any of the foregoing, the Party controlling any enforcement action pursuant to
Section 6.3 shall also have the sole right to control the response to any attack on the validity, title, or enforceability of a Patent that is asserted by the alleged infringer(s) as a counterclaim or affirmative defense in such action. Neither
Party shall have the right to settle any proceeding under this Section 6.4(b) in a manner that diminishes the rights or interests of the other Party without the prior written consent of such other Party, such consent not to be unreasonably
withheld or delayed. 
 6.5 Patent Marking. Mirum shall mark Licensed Product (or when the character of the product precludes
marking, the package containing any such Licensed Product) marketed and sold by Mirum or its Affiliates or their respective sublicensees hereunder in accordance with all applicable Laws relating to patent marking. 

6.6 Infringement of Third Party Rights. If any Compound or Licensed Product used or sold by Mirum or its Affiliates or their
respective sublicensees or subcontractors becomes the subject of a Third Party’s claim or assertion of infringement of a Patent granted by a jurisdiction within the Territory, Mirum shall promptly notify Shire, and the Parties shall agree on
and enter into a “common interest” or “joint defense” agreement wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute, and thereafter, the Parties shall promptly meet to consider the
claim or assertion and the appropriate course of action. Unless agreed otherwise by the Parties, Mirum shall be solely responsible for defending against any such claim or assertion, at its sole expense. Mirum shall keep Shire fully informed of such
claim and its defense, and shall reasonably consider and seek to accommodate any timely comments of Shire with respect thereto. 

  
 30 

	7.	 CONFIDENTIALITY 

7.1 Confidentiality Obligations. The Parties agree that, during the Term and for a period of [...***...] thereafter, each
Party shall: (a) use reasonable efforts to maintain in confidence the other Party’s Confidential Information (but not less than those efforts as such Party uses to maintain in confidence its own proprietary industrial information of
similar kind and value); (b) not disclose such Confidential Information to any Third Party without prior written consent of the other Party, except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties;
and (c) not use such other Party’s Confidential Information for any purpose except those permitted by this Agreement or in connection with exercising such Party’s or its Affiliates’ rights or fulfilling their obligations under
this Agreement. Shire and its Affiliates may not disclose any Shire Know-How to any Third Party to the extent such disclosure is in relation to a Compound or Licensed Product without the prior written consent
of Mirum, except (i) if such Shire Know-How becomes generally available to the public or otherwise part of the public domain, other than through any act or omission of the Shire or its Affiliates in
breach of this Agreement, (ii) if one of the exceptions in Section 7.3 applies to such Shire Know-How, or (iii) as set forth in Section 7.5(b). Notwithstanding anything to the contrary in
the definition of Confidential Information or this Article 7, with respect to any Confidential Information of Pfizer, Sanofi or Satiogen, including Pfizer Know-How, Sanofi
Know-How and Satiogen Know-How, from and following the Effective Date, such Confidential Information shall be deemed the Confidential Information of Mirum and Mirum
shall be the disclosing Party and Shire the receiving Party with respect to any such Confidential Information. 
 7.2
Exceptions. The obligations in Section 7.1 shall not apply with respect to any portion of the other Party’s Confidential Information that the receiving Party can show by competent written proof: 

(a) was known to the receiving Party (other than under an obligation of confidentiality or, in the case of Mirum employees or agents,
through their employment or service relationship with Lumena), at the time of disclosure by the other Party or its Affiliate; 
 (b)
was generally available to the public or otherwise part of the public domain, at the time of disclosure by the other Party or its Affiliate; 

(c) becomes generally available to the public or otherwise part of the public domain after the disclosure by the other Party, other than
through any act or omission of the receiving Party in breach of this Agreement; 
 (d) is subsequently disclosed to the receiving
Party by a Third Party who has a legal right to make such disclosure and who did not obtain such information directly or indirectly from the other Party; or 

(e) is subsequently independently developed by employees, subcontractors or sublicensees of the receiving Party or its Affiliates
without use of the other Party’s Confidential Information. 

  
 31 

 7.3 Authorized Disclosure. A Party may disclose the Confidential Information
belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances: 
 (a) filing or
prosecuting Patents in accordance with Section 6.2; 
 (b) complying with the requirement of Regulatory Authorities with respect
to making regulatory filings with Regulatory Authorities with respect to Compounds or Licensed Products, including seeking, obtaining and maintaining Regulatory Approval of Licensed Products; 

(c) prosecuting or defending litigation as contemplated by this Agreement; 

(d) disclosure to its or its Affiliates’ employees, directors, officers, agents, consultants, professional advisors,
subcontractors, licensees or sublicensees or bona fide potential subcontractors, licensees or sublicensees, on a need-to-know basis for the sole purpose of performing
its or its Affiliates’ obligations or exercising its or its Affiliates’ rights under this Agreement; provided that in each case, the disclosees are bound by written or professional obligations of confidentiality and nonuse consistent with
those contained in this Agreement; 
 (e) disclosure to any bona fide potential or actual investor, acquiror or merger partner or
other potential or actual financial or commercial partner for the sole purpose of evaluating an actual or potential investment, acquisition or other business relationship; provided that in connection with such disclosure, the disclosing Party shall
use all reasonable efforts to inform each disclosee of the confidential nature of such Confidential Information and cause each disclosee to treat such Confidential Information as confidential; or 

(f) complying with applicable Laws, including regulations promulgated by applicable security exchanges, court orders or administrative
subpoenas or orders. 
 Notwithstanding the foregoing, if a Party is required to make a disclosure of the other Party’s Confidential Information
pursuant to Sections 7.3(c) or 7.3(f), such Party shall promptly notify the other Party of such required disclosure and shall use reasonable efforts to assist the other Party, at such other Party’s expense, in preventing or limiting such
disclosure or obtaining confidential treatment, a protective order, or the like protecting such disclosure. 
 7.4 Publicity; Terms
of Agreement. 
 (a) The Parties will mutually agree to the text of a press release announcing the execution of this Agreement. If
either Party desires to make a public announcement concerning the material terms of this Agreement or activities conducted pursuant hereto, such Party shall give reasonable prior advance notice of the proposed text of such announcement to the other
Party for its prior review and approval (except as otherwise provided herein), such approval not to be unreasonably withheld, except that in the case of a press release or governmental filing required by applicable Law, the disclosing Party shall
provide the other Party with such advance notice as it reasonably can and shall not be required to obtain approval therefor. A Party commenting on such a proposed press release shall provide its comments, if any, within [...***...] after
receiving the press release for review. Neither Party shall be required to seek the permission of the other Party to repeat or disclose any information regarding the terms of this Agreement or any activities conducted pursuant hereto that has
already been publicly disclosed by such Party, or by the other Party, in accordance with this Section 7.4, provided such information remains accurate as of such time. 

  
 32 

 (b) The Parties acknowledge that either or both Parties may be obligated to file
under applicable Laws a copy of this Agreement with the U.S. Securities and Exchange Commission (“SEC”) or other Governmental Authorities. Each Party shall be entitled to make such a required filing, provided that it requests
confidential treatment of the commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably available to such Party and permitted by such Governmental Authority. In the event of any such filing, each
Party will provide the other Party with a copy of the Agreement marked to show provisions for which such Party intends to seek confidential treatment and shall reasonably consider and incorporate the other Party’s comments thereon to the extent
consistent with the legal requirements, with respect to the filing Party, governing disclosure of material agreements and material information that must be publicly filed. 

7.5 Technical Publications. 

(a) Mirum shall not require Shire’s consent to publish any Information related to a Compound or a Licensed Product as it determines
to be in the interests of Development, Manufacturing, obtaining Regulatory Approval and Commercialization of Compounds or Licensed Products; provided that Mirum must first secure Shire’s written consent prior to the disclosure of any of
Shire’s Confidential Information, not to be unreasonably withheld, conditioned or delayed. 
 (b) Shire shall not require
Mirum’s consent to make the publications described on Exhibit 7.5(b), provided that Shire provides a draft of such publications to Mirum for review and comment a reasonable time prior to the planned publication date. 

7.6 Prior Confidentiality Agreement. As of the Effective Date, the terms of this Article 7 shall supersede the Existing
Confidentiality Agreement. Any information disclosed by or on behalf of a Party or any of its Affiliates to the other Party or any of its Affiliates pursuant to the Existing Confidentiality Agreement shall be deemed Confidential Information of the
disclosing Party for purposes of this Agreement. 
 7.7 Return of Confidential Information. Upon the effective date of the
termination of this Agreement for any reason, either Party may request in writing, and the other Party shall either, with respect to Confidential Information to which such first Party does not retain rights under the surviving provisions of this
Agreement: (a) promptly destroy all copies of such Confidential Information in the possession of the other Party and confirm such destruction in writing to the requesting Party; or (b) promptly deliver to the requesting Party, at the other
Party’s expense, all copies of such Confidential Information in the possession of the other Party; provided that the other Party shall be permitted to retain one copy of such Confidential Information subject to an ongoing obligation of
confidentiality for the sole purpose of performing any continuing obligations hereunder or for archival purposes. In addition, such other Party also shall be permitted to retain such computer records or files containing such Confidential Information
that have been created solely by such Party’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such other Party’s standard archiving and back-up procedures, but not for any other use or purpose. 

  
 33 

	8.	 TERM AND TERMINATION 

8.1 Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article 8,
shall remain in effect on a country-by-country and Licensed Product-by-Licensed Product
basis, until the expiration of the Royalty Term of such Licensed Product in such country (the “Term”). On a Licensed Product-by-License Product and country-by-country basis, following expiration of the Royalty Term for a Licensed Product in a country, no further royalties shall be payable in respect of sales of such
Licensed Product in such country and thereafter the licenses to Shire Know-How granted to Mirum under Section 3.1 shall automatically become non-exclusive, fully paid-up, perpetual, irrevocable and royalty-free. 
 8.2 Termination for Material Breach.
Each Party shall have the right to terminate this Agreement in its entirety immediately upon written notice to the other Party if the other Party materially breaches its obligations under this Agreement and, after receiving written notice
identifying such material breach in reasonable detail, fails to cure such material breach within ninety (90) days from the date of such notice (or within ten (10) business days from the date of such notice if such material breach is solely
based on the breaching Party’s failure to pay any amounts due hereunder); provided, however, in the case of a breach or violation that cannot be cured within such ninety (90) day period, the breaching Party shall have an additional ninety
(90) day period to cure if the breaching Party shall have commenced substantial remedial actions within the initial ninety (90) day period and used and continues to use its best efforts to pursue the same. Any right to terminate under this
Section 8.2 shall be stayed and the cure period tolled in the event that, during any cure period, the breaching Party shall have, in good faith, initiated dispute resolution in accordance with Article 11 with respect to the alleged breach,
which stay and tolling shall last so long as the breaching Party diligently and in good faith cooperates in the prompt resolution of such dispute resolution proceedings. Each Party shall be entitled to offset, against amounts payable to the other
Party under this Agreement, any amounts of damages determined, in a final decision by the applicable court action or other legal proceeding (for which no appeal is available), to be owed to such Party by the other Party based on the other
Party’s material breach of this Agreement. Notwithstanding the foregoing, if Shire has the right to terminate this Agreement pursuant to this Section 8.2 and the sole basis for such right is Mirum’s material breach of its diligence
obligations in Section 5.6 with respect to SHP626 Licensed Products, then Shire’s right to terminate this Agreement shall only be with respect to the SBP626 Compounds and SBP626 Licensed Products and not with respect to the SBP625
Compounds, SBP625 Licensed Products or Other Licensed Products, subject to Section 8.6(b). 
 8.3 Termination Upon
Insolvency. Either Party may terminate this Agreement immediately upon written notice to the other Party, if, at any time, the other Party (a) files for protection under bankruptcy or insolvency Laws, (b) makes an assignment for the
benefit of creditors, (c) appoints or allows appointment of a receiver or trustee over substantially all of its property that is not discharged within [...***...] after such filing, (d) proposes a written agreement of composition,
arrangement, readjustment or extension of all of its debts, (e) is a party to any dissolution or liquidation or (f) has a petition under any bankruptcy or insolvency Laws involuntarily filed against it that is not discharged within
[...***...] of the filing thereof. 

  
 34 

 8.4 Termination for Patent Challenge; Payment. Immediately upon written notice
to Mirum, if Mirum or any of its Affiliates or their respective sublicensees or subcontractors of rights under this Agreement brings an action or proceeding that disputes the validity or enforceability of any Royalty Patents anywhere in the
Territory or files an opposition (or any equivalent action) against any of the Royalty Patents anywhere in the Territory, then Shire shall have the right to terminate this Agreement in its entirety or in part, on a country-by-country and Licensed Product-by-Licensed Product basis, at its election. Any such termination shall only become
effective if Mirum or such Affiliates or such sublicensees or subcontractors, as applicable, have not withdrawn such action prior to such written notice from Shire. 

8.5 Termination by Mirum. 

(a) If, after using Commercially Reasonable Efforts in accordance with Section 5.6, Mirum reasonably determines that it, or its
Affiliates or sublicensees, as applicable, is precluded from further Development of a Licensed Product because of [...***...], Mirum may, upon prior written notice to Shire, terminate this Agreement with respect to the SBP625 Compounds and
SBP625 Licensed Products (if such Licensed Product is an SBP625 Licensed Product) or the SBP626 Compounds and SBP626 Licensed Products (if such Licensed Product is an SBP626 Licensed Product). Any dispute between the Parties as to whether or not any
determination of Mirum pursuant to this Section 8.5(a) is “reasonable” shall be determined in accordance with Article 11. 

(b) Mirum may terminate this Agreement in its entirety for any reason, upon ninety (90) days’ prior written notice to Shire given
at any time after the third (3rd) anniversary of the Effective Date. 
 8.6 Effects of Termination of this Agreement. Upon any
termination of this Agreement, in its entirety or on a country-by-country or Licensed
Product-by-Licensed Product basis: 
 (a)
Termination of License to Mirum. All rights and licenses granted to Mirum hereunder shall terminate, but in the case of termination in part, only to the extent such rights and licenses relate to the country(ies) and Licensed Product(s) that
are the subject of such termination, and the provisions of the last sentence of Section 3.2 shall apply to agreements with respect to the terminated country(ies) and Licensed Product(s). In addition, Section 3.6 shall terminate. 

(b) Assignment of Assigned Agreements. Upon Shire’s written request, to the extent of any Assigned Agreement that is in
effect upon the effective date of termination and subject to any consent required of any counterparty to the applicable Assigned Agreement (which Mirum shall use good faith efforts to secure at no cost to Mirum), Mirum shall assign (or cause to be
assigned) to Shire (or its designated Affiliate) any or all of such Assigned Agreements and shall execute such documents, and perform such other acts, as may be necessary or appropriate in order to effectuate such assignment. Shire (or its
designated Affiliate) will (A) accept the assignment of such Assigned Agreements and agree to timely perform, pay and discharge, as and when due, all 

  
 35 

 
duties and obligations of Mirum and its Affiliates under the Assigned Agreements to the extent arising after the effective date of such assignment excluding all liabilities arising from any
failure by Mirum or its Affiliates to timely perform, pay and discharge, as and when due, all duties and obligations of Mirum and its Affiliates under the Assigned Agreements prior to such effective date, which shall remain liabilities of Mirum or
its Affiliates, and (B) agrees to be substituted for Mirum or its Affiliate, as applicable, as a party to the Assigned Agreements from and after the effective date of such assignment. Notwithstanding the foregoing, if termination is by Shire
solely with respect to the SHP626 Compounds and SHP626 Licensed Products in accordance with the last sentence of Section 8.2, then (i) in lieu of assignment of the Satiogen Agreement to Shire, at Shire’s request, to the extent the
Satiogen Agreement is in effective upon the effective date of such termination, Mirum shall and hereby does delegate to Shire all of Mirum’s rights under the Satiogen Agreement regarding the preparation, filing, prosecution, maintenance,
defense and enforcement of the Satiogen Patents and Mirum shall cooperate with Shire in accordance therewith pursuant to Sections 6.2(e) and 6.3(c), mutatis mutandis, and Shire shall, and hereby does, accept all responsibility and liability for the
performance of such activities delegated to it, and (ii) if Shire does not request assignment of the Sanofi Agreement, to the extent the Sanofi Agreement is in effective upon the effective date of such termination, Mirum must either comply with
the Sanofi Agreement or terminate the Sanofi Agreement in accordance with its terms and, if Mirum does not terminate the Sanofi Agreement, at Shire’s request, Mirum shall and hereby does delegate to Shire all of Mirum’s rights under the
Sanofi Agreement regarding the preparation, filing, prosecution, maintenance, defense and enforcement of the Sanofi Patents and Mirum shall cooperate with Shire in accordance therewith pursuant to Sections 6.2(e) and 6.3(c), mutatis mutandis, and
Shire shall, and hereby does, accept all responsibility and liability for the performance of such activities delegated to it. 
 (c)
License to Shire. Mirum (on behalf of itself and its Affiliates) shall, and hereby does, grant to Shire, effective only and automatically as of the effective date of such termination of this Agreement, only to the extent such licenses relate
to the country(ies) and Licensed Product(s) that are the subject of such termination, an exclusive license, with the right to sublicense (through multiple tiers), under Arising IP and any other Patents and Information Controlled by Mirum or its
Affiliates (excluding any Acquiror or Acquiror Affiliates that became Affiliates of Mirum as a result of a Change in Control of Mirum) as of the effective date of such termination that are necessary or reasonably useful to develop, have developed,
make, have made, use, offer to sell, sell, have sold and import Compounds and Licensed Products in the Field for the sole purpose of developing, having developed, making, having made, using, offering to sell, selling, having sold and importing
Compounds and Licensed Products in the Field. Such license shall be [...***...] except in the case of termination by Mirum for Shire’s material breach pursuant to Section 8.2, in which case Shire shall pay to Mirum a royalty of
[...***...] of Net Sales (applied to Shire in the same manner as applied to Mirum under Section 4.5, excluding Section 4.5(d)). Notwithstanding the foregoing, (i) the license granted under this provision shall only include
Patents or Information Controlled by Mirum or its Affiliate (other than any Acquiror or Acquiror Affiliate) pursuant to any Assigned License Agreement if Shire requests that Mirum assign such Assigned License Agreement to it but Mirum is not able to
do so pursuant to clause (b) above, and (ii) if the license granted under this provision includes Patents or Information Controlled by Mirum or its Affiliate (other than any Acquiror or Acquiror Affiliate) pursuant to an agreement with a
Third Party then the license or sublicense to Shire hereunder, and any right of 

  
 36 

 
Shire to grant a further sublicense thereunder, shall be subject and subordinate to the terms and conditions of the applicable agreement between Mirum and such Third Party, including, without
limitation, any payment obligations to such Third Party as a result of practice of such license or sublicense, and shall be effective solely to the extent permitted under the terms of such agreement(s). 

(d) Trademarks. Mirum and its Affiliates shall assign to Shire all right, title and interest in and to any and all trademarks for
the terminated Licensed Product(s), including any pending trademark applications for such trademarks (solely to the extent owned by Mirum or its Affiliates as of the effective date of such termination), worldwide, or in the terminated country(ies),
as applicable (excluding any trademarks that include any corporate name or logo of Mirum or its Affiliates). 
 (e) Regulatory
Materials; Data. As permitted by applicable Laws, Mirum shall transfer and hereby assigns to Shire all Regulatory Materials and Regulatory Approvals for the terminated Licensed Product(s) (solely to the extent owned or Controlled by Mirum or its
Affiliates as of the effective date of such termination), worldwide, or in the terminated country(ies), as applicable. To the extent such assignment is not permitted by applicable Law, Mirum hereby grants to Shire a license and right of reference
under such Regulatory Materials and Regulatory Approvals. 
 (f) Ongoing Clinical Trials. If this Agreement is terminated while
any clinical trial for the terminated Licensed Product(s), worldwide, or in the terminated country(ies), as applicable, is ongoing, Mirum shall notify Shire of its decision either to continue or wind down all such trials which, in each case, shall
be at Mirum’s sole cost and expense. The Parties shall negotiate in good faith and adopt a plan to wind-down such Development activities in an orderly fashion (not to exceed [...***...]) or, at Shire’s election, promptly transition
such Development activities to Shire, with due regard for patient safety and the rights of any subjects that are participants in any clinical trials of any terminated Licensed Products, and Mirum, at Shire’s expense, shall take any actions
Shire deems reasonably necessary or appropriate to avoid any human health or safety problems and in compliance with all applicable Laws. 

(g) Transition Assistance. Promptly upon request by Shire, but in no event commencing later than [...***...] after the
effective date of termination, Mirum shall, with respect to the terminated Licensed Product(s), worldwide, or in the terminated country(ies), as applicable, at Mirum’s reasonable expense (except in the case of termination by Mirum for
Shire’s material breach, in which case it shall be at Shire’s expense) in accordance with a budget agreed to in writing by the Parties (such agreement not to be unreasonably withheld, conditioned or delayed), (i) work with Shire to
facilitate the timely transfer to Shire of all Information licensed to Shire under Section 8.6(b) and copies of all Regulatory Materials and Regulatory Approvals assigned to Shire under Section 8.6(e) and (ii) provide such other
assistance, as may be necessary or reasonably useful for Shire to commence or continue Developing, Manufacturing or Commercializing the terminated Compound(s) and Licensed Product(s) in the terminated country(ies) to the extent Mirum is then
performing or having performed such activities, including, upon request of Shire, transferring to Shire as permitted any agreements or arrangements with Third Party vendors to Develop, Manufacture, distribute, sell, or otherwise Commercialize such
Licensed Product(s) in such country(ies). 

  
 37 

 (h) Interim Supply. At Shire’s written request, Mirum shall use
Commercially Reasonable Efforts to facilitate the supply to Shire, from either Mirum (or its Affiliates) or from Mirum’s contract manufacturers, of Shire’s requirements for Compound and Licensed Product for a period of [...***...],
provided that, except in the case of termination by Shire for Mirum’s material breach pursuant to Section 8.2, Shire reimburses Mirum for all reasonable
out-of-pocket costs incurred by Mirum in connection with such activities. 

(i) Remaining Inventories. If this Agreement is terminated in its entirety, Mirum or its Affiliates or their respective
subcontractors or sublicensees, to the extent that such parties continue to have stocks of usable Licensed Products, may continue to fulfill orders received for Licensed Products in the Field until [...***...] following the date of
termination. For Licensed Products sold by Mirum or its Affiliates or their respective subcontractors or sublicensees after the effective date of a termination, Mirum shall continue to pay royalties pursuant to Section 4.5. Prior to the end of
such [...***...] period, Mirum shall provide Shire with a written notice of an estimate of the quantity of Licensed Products (or components thereof) and shelf life remaining in the inventory of Mirum at the end of such [...***...] period
and Shire shall have the right to purchase any or all of the inventory of Licensed Products (or components thereof) held by Mirum as of the date of such termination (that are not committed to be supplied to any Third Party or sublicensee or
subcontractor, in the ordinary course of business, as of the date of termination) at a price of [...***...] of Mirum’s actual cost of goods. For clarity, this Section 8.6(i) does not permit the manufacture or sale of any Licensed
Product that was not in stock on the effective date of the termination. 
 8.7 Remedy in Lieu of Termination by Mirum under
Section 8.2. If Mirum has the right to terminate this Agreement in its entirety under Section 8.2 for Shire’s uncured material breach, Mirum may elect, by written notice to Shire, to, in lieu of termination of this
Agreement, continue this Agreement, in which case Mirum’s obligations under Sections 3.6 and 5.6 will terminate but all other terms will continue to apply. 

8.8 Damages; Relief. Termination of this Agreement shall not preclude either Party from claiming any other damages, compensation
or relief that it may be entitled to upon such termination; provided, however, that the value of all rights granted to Shire upon termination of this Agreement pursuant to Section 8.6 shall be taken into account in any calculation of damages,
compensation or relief available to Shire upon termination. 
 8.9 Survival. Termination or expiration of this Agreement shall
not affect any rights or obligations of the Parties under this Agreement that have accrued prior to the date of termination or expiration. Notwithstanding anything to the contrary, the following provisions shall survive any expiration or termination
of this Agreement: Article 1, Section 2.1 (unless and until the applicable Assigned Agreement is assigned to Shire or its Affiliate pursuant to Section 8.6(b)), Section 3.2 (with respect to subclauses (a) through (c) and the last
sentence), Section 3.5, Section 4.6, Section 4.7, Section 4.8 (for the time period set forth therein), Section 4.8, Section 4.9, Section 6.1, Article 7, Section 8.1 (with respect to the last sentence in the
case of licenses that have become perpetual prior to termination or expiration of this Agreement), Section 8.6 (as applicable), Section 8.8, Section 8.9, Section 9.5, Section 10.1, Section 10.2, Section 10.3 (for
six (6) years after termination or expiration), Article 11 and Article 12. 

  
 38 

	9.	 REPRESENTATIONS AND WARRANTIES AND COVENANTS 

9.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party as follows: 

(a) Corporate Existence. As of the Effective Date, it is a company or corporation duly organized, validly existing, and in good
standing under the Laws of the jurisdiction in which it is incorporated. 
 (b) Corporate Power, Authority and Binding
Agreement. As of the Effective Date, (i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part
required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and
binding obligation of such Party that is enforceable against it in accordance with its terms. 
 (c) No Conflicts. The
execution and delivery of this Agreement, and the performance by such Party of its obligations under this Agreement, including the grant of rights and licenses to the other Party pursuant to this Agreement, does not and will not: (i) conflict
with, nor result in any violation of or default under, any instrument, judgment, order, writ, decree, contract or provision to which such Party is bound; (ii) give rise to the suspension, revocation, impairment, forfeiture or non-renewal of any material permit, license, authorization or approval that applies to such Party, its business or operations or any of its assets or properties; or (iii) conflict with any rights granted by
such Party to any Third Party or breach any obligation that such Party has to any Third Party. 
 9.2 Additional Representations
and Warranties of Mirum. Mirum represents and warrants to Shire that: 
 (a) No Debarment. As of the Effective Date,
neither Mirum, nor any of its Affiliates, has any employee or consultant who is or has been debarred by any Regulatory Authority or, to Mirum’s Knowledge, is the subject of debarment proceedings by a Regulatory Authority. 

(b) Sufficient Resources. Upon Mirum’s receipt of the funds contemplated by the Investment Agreements, Mirum will have
sufficient resources to conduct the Development of the Compounds and Licensed Product through the end of calendar year 2019. 
 9.3
Additional Representations, Warranties and Covenants of Shire. Shire represents, warrants and covenants to Mirum that, as of the Effective Date: 

(a) Shire IP. Shire is the sole and exclusive owner or licensee of the Shire Patents and Shire
Know-How, free and clear of all liens, and Shire has the right to grant the licenses to the Shire Patents that it purports to grant to Mirum hereunder. 

  
 39 

 (b) No Conflicting Grant of Rights. Shire has not as of the Effective Date,
and will not during the Term, grant any right to any Third Party under the Shire IP that would conflict with the rights granted to Mirum hereunder. 

(c) No Claims or Proceedings. There are no pending actions, claims, investigations, suits or proceedings against Shire or any of
its Affiliates, at law or in equity, or before or by any Regulatory Authority, and neither Shire nor any of its Affiliates has received any written notice regarding any pending or threatened actions, claims, investigations, suits or proceedings
against Shire or any of its Affiliates, at Law or in equity, or before or by any Regulatory Authority, in either case with respect to the Shire IP, and no Shire Patent is the subject of any interference, opposition, cancellation or other protest
proceeding. 
 (d) Assigned Agreements. Shire owns and has good and valid title, or possesses the right to assign its and its
Affiliates’ interest therein, to all of the Assigned Agreements, free and clear of all liens, claims and encumbrances. Shire has the right to assign, transfer and convey the Assigned Agreements or to sublicense the rights thereunder to Mirum as
contemplated by Sections 2.1 and 2.2. Each of the Assigned Agreements is in full force and effect in accordance with its terms. Shire and its Affiliates are in compliance in all material respects with its obligations under each of the Assigned
Agreements and, to Shire’s Knowledge, (i) no other party to any of the Assigned Agreements has breached such agreement in any material respect, and (ii) there is no basis for termination of any of the Assigned Agreements based on
Shire’s material breach. To the extent available as a result of the execution, delivery or performance of this Agreement, Sanofi’s right of first negotiation under Section 2.8 of the Sanofi Agreement has expired and Pfizer indicated
it was not interested in exercising its option under Section 2.5 of the Pfizer Agreement. After giving effect to Article 2 in its entirety, the execution, delivery or performance of this Agreement by Shire will not, with or without notice or
the lapse of time, result in or give any other party to any Assigned License Agreement the right or option (which has not been waived) to cause or declare a material breach of or to terminate any Assigned License Agreement. Neither Shire nor any of
its Affiliates has granted any right to any Third Party under any Assigned License Agreement or any intellectual property licensed to Shire or its Affiliates under any Assigned License Agreement. 

(e) No Infringement. Neither Shire nor any of its Affiliates has received any written notice of any unauthorized use,
infringement, misappropriation, or dilution by any person, including any current or former employee or consultant of Shire or its Affiliates, of the Shire IP, Pfizer Know-How, Sanofi Know-How, Sanofi Patents, Satiogen Know-How or Satiogen Patents, and to Shire’s Knowledge, no Third Party is infringing or misappropriating or has infringed or
misappropriated the Shire IP, Pfizer Know-How, Sanofi Know-How, Sanofi Patents, Satiogen Know-How or Satiogen Patents. 

(f) No Debarment. In the course of the Development or Manufacture of Licensed Products or manufacture of Compounds, neither
Shire, nor its Affiliates has used any employee or consultant who has been debarred by any Regulatory Authority or, to Shire’s or its Affiliates’ Knowledge, is the subject of debarment proceedings by a Regulatory Authority. 

  
 40 

 9.4 Covenants of Mirum. Mirum covenants to Shire as follows: 

(a) No Debarment. In the course of the Development or Manufacture of Licensed Products or manufacture of Compounds, neither
Mirum, nor its Affiliates or their respective sublicensees or subcontractors shall use any employee or consultant who has been debarred by any Regulatory Authority or, to Mirum’s or its Affiliates’ Knowledge, is the subject of debarment
proceedings by a Regulatory Authority. Mirum shall notify Shire promptly upon becoming aware that any of its or its Affiliates’, or their respective sublicensees’ or subcontractors’ employees or consultants has been debarred or is the
subject of debarment proceedings by any Regulatory Authority. 
 (b) Compliance. Mirum and its Affiliates shall comply with all
applicable Laws in the Development, Manufacture and Commercialization of the Licensed Products, including the statutes, regulations and written directives of the FDA, the EMA and any other Regulatory Authorities, the Federal Food, Drug &
Cosmetic Act, as amended, the Prescription Drug Marketing Act, the Federal Health Care Programs Anti-Kickback Law, 42 U.S.C. § 1320a-7b(b), the statutes, regulations and written directives of Medicare, Medicaid and all other health care
programs, as defined in 42 U.S.C. § 1320a-7b(f), and the Foreign Corrupt Practices Act of 1977, each as may be amended from time to time. 

(c) Assigned License Agreements. Mirum shall not amend or waive, and shall not take any action or omit to take any action under
the Assigned License Agreements that would (i) increase any payments that may be due by Shire or materially and adversely reduce the scope of the license granted to Shire if such Assigned License Agreement were assigned to Shire upon
termination of this Agreement or (ii) reduce any payments to Shire under this Agreement. Mirum shall promptly notify Shire of, and provide details and copies of associated documentation of, any default under, termination or amendment of, any
Assigned License Agreement. 
 9.5 Disclaimer. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES
WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD
PARTY PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY, AND ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY DISCLAIMED AND EXCLUDED. 

 

	10.	 INDEMNIFICATION AND LIMITATION OF LIABILITY 

10.1 Indemnification. 

(a) Indemnification by Mirum. Mirum shall defend, indemnify, and hold Shire and its Affiliates and their respective officers,
directors, employees, and agents (the “Shire Indemnitees”) harmless from and against any and all damages or other amounts payable to a Third Party claimant, as well as any reasonable attorneys’ fees and costs of litigation
incurred by such Shire Indemnitees, all to the extent resulting from claims, suits, proceedings, or causes of action brought by such Third Party (“Claims”) against such Shire Indemnitees that arise from or are based on: (i) the
Development, Manufacture, or Commercialization of Licensed Products or Compounds (including any performance of the Existing Trials after sponsorship is transitioned to Mirum) by or on behalf of Mirum or its Affiliates or their respective
sublicensees or subcontractors 

  
 41 

 
(excluding in all cases Shire or its Affiliates), (ii) the breach of any of Mirum’s obligations under this Agreement including Mirum’s representations, warranties, or covenants set
forth herein, (iii) the willful misconduct or negligent acts of Mirum or any of its Affiliates or any of their respective officers, directors, employees or agents, or (iv) any liability arising from failure to timely perform, pay and
discharge, as and when due, all duties and obligations of Shire and its Affiliates (Mirum and its Affiliates after assignment) under any Assigned Agreement to the extent allocated to Mirum in Section 2.1. The foregoing indemnity obligation
shall not apply to the extent to the extent that any of the Claims arises from, is based on, or results from any activity set forth in Section 10.1(b)(i), (ii) (iii) or (iv) for which Shire is obligated to indemnify the Mirum Indemnitees
under Section 10.1(b). 
 (b) Indemnification by Shire. Shire shall defend, indemnify, and hold Mirum and its Affiliates
and their respective officers, directors, employees, and agents (the “Mirum Indemnitees”) harmless from and against any and all damages or other amounts payable to a Third Party claimant, as well as any reasonable attorneys’
fees and costs of litigation incurred by such Mirum Indemnitees, all to the extent resulting from Claims against such Mirum Indemnitees that arise from or are based on: (i) the Development, Manufacture, or Commercialization of Licensed Products
or Compounds (including any performance of the Existing Trials before sponsorship is transitioned to Mirum) by or on behalf of Shire or its Affiliates or their respective sublicensees or subcontractors under any license granted pursuant to
Section 8.6(b), (ii) the breach of any of Shire’s obligations under this Agreement including of Shire’s representations, warranties, or covenants set forth herein; (iii) the willful misconduct or negligent acts of Shire or any of
its Affiliates or any of their respective officers, directors, employees or agents or (iv) any liability arising from failure to timely perform, pay and discharge, as and when due, all duties and obligations of Shire and its Affiliates (Mirum
and its Affiliates after assignment) under any Assigned Agreement to the extent allocated to Shire in Section 2.1. The foregoing indemnity obligation shall not apply to the extent that any of the Claims arises from, is based on, or results from
any activity set forth in Section 10.1(a)(i), (ii), (iii) or (iv) for which Mirum is obligated to indemnify the Shire Indemnitees under Section 10.1(a). 

  
 42 

 (c) Indemnification Procedures. The Party seeking indemnification
(individually, the “Indemnified Party”) shall promptly notify the other Party (the “Indemnifying Party”) in writing of the Claim. Such Claim for indemnity shall indicate the nature of the Claim and the basis
therefor. Promptly after a Claim is made for which the Indemnified Party seeks indemnity, the Indemnified Party shall permit the Indemnifying Party, at its option and expense, to assume the complete defense of such Claim, provided that (i) the
Indemnified Party will have the right to participate in the defense of any such Claim at its own cost and expense, (ii) the Indemnifying Party will conduct the defense of any such Claim with due regard for the business interests and potential
related liabilities of the Indemnified Party, and (iii) the Indemnifying Party will not agree to any settlement that would admit liability on the part of the Indemnified Party or involve relief other than payment of money, without the approval
of the Indemnified Party, not to be unreasonably withheld; and provided, further, that if it is reasonably likely that the Parties may have conflicting interests or if it is otherwise not advisable under applicable legal and ethical requirements for
the Indemnifying Party’s defense counsel to represent both Parties, separate independent counsel shall be retained for each Party at its own expense. The Indemnifying Party will not, in defense of any such Claim, except with the consent of the
Indemnified Party, consent to the entry of any judgment or enter into any settlement which does not include, as an unconditional term thereof, the giving by the claimant or plaintiff to the Indemnified Party of a release from all liability in
respect thereof. After notice to the Indemnified Party of the Indemnifying Party’s election to assume the defense of such Claim, the Indemnifying Party shall be liable to the Indemnified Party for such legal or other expenses subsequently
incurred by the Indemnified Party in connection with the defense thereof at the request of the Indemnifying Party. As to those Claims with respect to which the Indemnifying Party does not elect to assume control of the defense, the Indemnified Party
will afford the Indemnifying Party an opportunity to participate in such defense at the Indemnifying Party’s own cost and expense, and will not settle or otherwise dispose of any of the same without the consent of the Indemnifying Party. 

10.2 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR
INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 10.2 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE
INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 10.1 OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 7. 

10.3 Insurance. Each Party shall procure and maintain insurance, including product liability insurance, with respect to its
activities hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which any Licensed Product is being clinically tested in human subjects or commercially distributed or sold. Each
Party shall provide the other Party with certificate of insurance evidencing of such insurance upon request and shall provide the other Party with written notice at least thirty (30) days prior to the cancellation, non-renewal or material changes in such insurance. It is understood that such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under
this Article 10. 

  
 43 

	11.	 DISPUTE RESOLUTION 

11.1 Disputes. The Parties recognize that disputes as to certain matters may from time to time arise that relate to either
Party’s rights or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to
litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 11 to resolve any controversy or claim arising out of, relating to or in connection with any provision of this Agreement, if and when a
dispute arises under this Agreement. 
 11.2 Internal Resolution; Mediation. With respect to all disputes arising between the
Parties under this Agreement, including any alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement, if the Parties are unable to resolve such dispute within [...***...] after such
dispute is first notified by either Party in writing to the other, the Parties shall refer such dispute to the Executive Officers (or their designees) for attempted resolution by good faith negotiations within [...***...] after such notice is
received, including at least [...***...] in person [...***...] of the Executive Officers within [...***...] after such notice is received. If the Executive Officers of the Parties are not able to resolve such disputed matter within
[...***...] and either Party wishes to pursue the matter, the Parties agree to submit the disputed matter for non-binding mediation (with the understanding that the role of the mediator shall not be to
render a decision but to assist the Parties in reaching a mutually acceptable resolution), for a period of not more than [...***...]. 

11.3 Binding Arbitration. If the disputed matter is not resolved by non-binding mediation
under Section 11.2 within [...***...] and either Party wishes to pursue the matter, each such dispute, controversy or claim, subject to Section 11.4, shall be finally resolved by binding arbitration administered by the International
Chamber of Commerce (“ICC”) pursuant to its Dispute Resolution Rules then in effect, and judgment on the arbitration award may be entered in any court having jurisdiction thereof. The Parties agree that: 

(a) The arbitration shall be conducted by a panel of three persons experienced in the pharmaceutical business. Within [...***...]
after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within [...***...] of their appointment. If the arbitrators selected by the Parties
are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by the ICC. The place of arbitration shall be New York, New York, and all proceedings and communications shall be in English. 

(b) Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy
is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the
arbitration award. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damage. Each Party shall bear its own costs and expenses and attorneys’ fees and an equal
share of the arbitrators’ fees and any administrative fees of arbitration, unless the arbitrators determine that a Party has incurred unreasonable expense due to vexatious or bad faith position taken by the other Party, in which event, the
arbitrators may make an award of all or any portion of such expenses so incurred. 

  
 44 

 (c) Reasons for the arbitrators’ decisions should be complete and explicit,
including reasonable determinations of law and fact. The written reasons should also include the basis for any damages awarded and a statement of how the damages were calculated. Such a written decision shall be rendered by the arbitrators following
a full comprehensive hearing, no later than [...***...] following the selection of the arbitrators under
 Section 11.3(a). 

(d) Except to the extent necessary to confirm an award or as may be required by applicable Laws, neither Party nor any arbitrator may
disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute,
controversy or claim would be barred by the applicable statute of limitations. 
 11.4 Patent Disputes. Notwithstanding
Section 11.3, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Patent covering the manufacturing, use, importation, offer for sale, or sale of a Compound or Licensed Product shall be
submitted to a court of competent jurisdiction in the country in which such Patent was granted. 
  

	12.	 MISCELLANEOUS 

12.1 Entire Agreement; Amendments. This Agreement, including the Exhibits hereto, the Investment Agreements and the Transition
Services Agreement sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and
thereof, and supersedes all prior agreements and understandings between the Parties with respect to the subject matter hereof and thereof, including the Existing Confidentiality Agreement. There are no covenants, promises, agreements, warranties,
representations, conditions or understandings, either oral or written, between the Parties other than as are set forth in this Agreement. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties
unless reduced to writing and signed by an authorized officer of each Party. 
 12.2 Force Majeure. Each Party shall be excused
from the performance of its obligations under this Agreement to the extent that such performance is prevented by force majeure (as defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse
shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement, “force majeure” shall include conditions beyond
the control of the Parties, including an act of God, war, civil commotion, terrorism, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production
facilities or materials by fire, earthquake, storm or like catastrophe. Notwithstanding the foregoing, the payment of amounts due and owing hereunder shall in no event be delayed by the payor because of a force majeure affecting the payor. 

  
 45 

 12.3 Notices. Any notices given under this Agreement shall be in writing,
addressed to the Parties at the following addresses, and delivered by person, by facsimile (with receipt confirmation), or by FedEx or other reputable courier service. Any such notice shall be deemed to have been given: (a) as of the day of
personal delivery; (b) one day after the date sent by facsimile service; or (c) on the day of successful delivery to the other Party confirmed by the courier service. Unless otherwise specified in writing, the mailing addresses of the
Parties shall be as described below. 
 If to Mirum: 

Mirum Pharmaceuticals, Inc. 

12230 El Camino Real, Suite 230 

San Diego, CA 92130 
 Attention:
Chief Executive Officer 
 With a copy (which shall not constitute notice) to: 

Cooley LLP 
 4401 Eastgate Mall

 San Diego, CA 92121-1909 

Attention: Kay Chandler 
 FAX:
+1 858 550 6420 
 If to Shire: 

Shire International GmbH 

Zahlerweg 10 
 6300 Zug –
Switzerland 
 Attention: Legal Department 

With copies (which shall not constitute notice) to: 

Shire 
 650 East Kendall St.

 Cambridge, MA 02142 

Attention: General Counsel 
 and

 Morgan, Lewis & Bockius LLP 

502 Carnegie Center 
 Princeton,
NJ 08540-6241 
 Attention: Randall Sunberg 

FAX: 1.609.919.6701 
 12.4
Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment without the other Party’s consent to
its Affiliates, including in connection with any re-domiciling of such Party or its Affiliates, or to a Third Party successor to 

  
 46 

 
substantially all of the business of such Party to which this Agreement relates (such Third Party, an “Acquiror”), whether in a merger, sale of stock, sale of assets or other
transaction. Any permitted assignment shall be binding on the successors of the assigning Party and any Acquiror or successor or assignee of a Party’s rights or obligations hereunder shall, in writing to the other Party, expressly assume
performance of such Party’s rights or obligations under this Agreement. Any assignment or attempted assignment by either Party in violation of the terms of this Section 12.4 shall be null, void and of no legal effect. 

12.5 Performance by Affiliates. Each Party may discharge any obligations and exercise any right hereunder through any of its
Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any
breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such
Party’s Affiliate. 
 12.6 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

12.7 Severability. If any of the provisions of this Agreement are held to be invalid or unenforceable by any court of competent
jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid
or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

12.8 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or
other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time.

 12.9 Independent Contractors. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall
be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture partners between the
Parties. 
 12.10 Governing Law. Resolution of all disputes, controversies or claims arising out of, relating to or in
connection with this Agreement or the performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of New York, U.S., without regard
to conflicts of law rules. 
 12.11 Equitable Relief. Each Party acknowledges that its breach of Article 7, and Mirum
acknowledges that its breach of Section 3.6, may cause irreparable harm to the other Party, which cannot be reasonably or adequately compensated in damages in an action at law. 

  
 47 

 
By reasons thereof (and notwithstanding Article 10), each Party agrees that the other Party shall be entitled, in addition to any other remedies it may have under this Agreement or otherwise, to
preliminary and permanent injunctive and other equitable relief to prevent or curtail any actual or threatened breach of the obligations relating to Confidential Information set forth in Article 7 by the other Party or in Section 3.6 by Mirum.

 12.12 Cumulative Remedies. The rights and remedies provided herein are cumulative and do not exclude any other right or
remedy provided by applicable Law or otherwise available except as expressly set forth herein. 
 12.13 No Benefit to Third
Parties. Except as provided in Article 10, covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns, and they shall not be construed as conferring any rights
on any Third Party. 
 12.14 Construction of this Agreement. When used in this Agreement, the term “including”,
“include” or “includes” means including, without limiting the generality of any description preceding the term. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the
singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). References to either Party include the successors and permitted assigns of that Party. The headings of this
Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The Parties have each consulted counsel of their choice
regarding this Agreement and have jointly prepared this Agreement, and, accordingly, no provisions of this Agreement shall be construed against either Party on the basis that the Party drafted this Agreement or any provision thereof. If the terms of
this Agreement conflict with the terms of any Exhibit, then the terms of this Agreement shall govern. This Agreement has been prepared in the English language and English shall control its interpretation. 

12.15 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and
all of which shall constitute together the same document. Counterparts may be signed and delivered by facsimile, or electronically in PDF format, each of which shall be binding when sent. 

{Signature Page Follows} 

  
 48 

 IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate originals
by their proper officers as of the Effective Date. 
  

									
	MIRUM PHARMACEUTICALS, INC.	  	    	  	SHIRE INTERNATIONAL GMBH
					
	By:	  	 /s/ Michael Grey
	  		  	By:	  	 /s/ Ramy Riad

	Title:	  	 Chief Executive Officer
	  		  	Title:	  	 Head of Finance International

	Date:	  	  
	  		  	Date:	  	  

 {Signature Page to Assignment and License Agreement} 

 EXECUTION VERSION 

EXHIBIT 1.12(A) 
 SHP625 COMPOUND

 [...***...] 

 EXECUTION VERSION 

EXHIBIT 1.12(B) 
 SHP626 COMPOUND

 [...***...] 

 EXECUTION VERSION 

EXHIBIT 1.53 
 SANOFI PATENTS 

 

									
	 Title
	  	Juris.	 	  	Appl. No.
Pub. No./Grant No.	  	Status
Filing Date
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]

									
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]

									
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]

 EXECUTION VERSION 

EXHIBIT 1.56 
 SATIOGEN PATENTS

  

							
	 Title
	  	Juris.	  	Appl. No.
Pub. No./Grant No.	  	Status
Filing Date
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]

 EXECUTION VERSION 

EXHIBIT 1.59 
 SHIRE PATENTS 

 

									
	 Title
	  	Juris.	 	  	Appl. No.
Pub. No./Grant No.	  	Status
Filing Date
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]
	 [...***...]
	  	 	[...***...]	 	  	[...***...]	  	[...***...]

													
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 

 EXECUTION VERSION 

EXHIBIT 5.2(b) 
 DEVELOPMENT PLAN

 MARALIXIBAT (“MRX”) 
 [...***...]

 Shire had significant interactions with regulatory agencies which have [...***...]. Mirum intends to [...***...]. The goal is
[...***...]. [...***...]: 
 1. [...***...] 

2. [...***...] 
 3.
[...***...] 
 [...***...] Study 
 The
[...***...] study will be [...***...] with the [...***...]: 
 1. [...***...] 

2. [...***...] 
 3.
[...***...] 
 Once the [...***...] is [...***...]. 

[...***...] Study 
 [...***...]. 

[...***...]. 
 [...***...]. 

[...***...]. 
 [...***...] Study 

[...***...]. 
 [...***...]. 

[...***...] 
 Mirum also intends to [...***...]: 

 

	 	•	 	 [...***...] 

  

	 	•	 	 [...***...] 

  

	 	•	 	 [...***...] 

	 	•	 	 [...***...] 

  

	 	•	 	 [...***...] 

  

	 	•	 	 [...***...] 

  

	 	•	 	 [...***...] 

[...***...]. 
 [...***...] 

[...***...]. 
 [...***...] 

[...***...] 
 [...***...]. 

 EXECUTION VERSION 

EXHIBIT 5.2(d) 
 INITIAL KNOW-HOW AND MATERIAL TRANSFER 
 The following will be provided only to the extent available in written or electronic
format, in such written or electronic format as it is held by Shire or its Affiliates: 
  

					
	 Item
	  	Timing (days after
Effective Date)	  	Comment
	 [...***...]
	  	[...***...]	  	
	 [...***...]
	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	
	 [...***...]
	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	

 EXECUTION VERSION 

EXHIBIT 5.3(b) 
 EXISTING TRIALS

  

					
	 Name
	  	NCT number	 
	 [...***...]
	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 
	 [...***...]
	  	 	[...***...]	 

 EXECUTION VERSION 

EXHIBIT 7.5(b) 
 AUTHORIZED SHIRE
PUBLICATIONS 
  

	 	•	 	 [...***...]. 

  

	 	•	 	 [...***...].EX-10.21

 Exhibit 10.21 

TRANSITION SERVICES AGREEMENT 

This Transition Services Agreement (this “Agreement”) is dated as of January 28, 2019 (the
“Execution Date”), by and between Mirum Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (“Mirum”), and Shire International GmbH, a company
organized under the laws of Switzerland (“Shire”). Mirum and Shire may be referred to herein individually as a “Party” and together as the “Parties”. 

RECITALS 
 A. Mirum and
Shire entered into the certain Assignment and License Agreement, dated November 5, 2018 (the “Assignment and License Agreement”), pursuant to which Mirum was assigned certain agreements and was granted an exclusive
worldwide license under intellectual property owned by Shire or its Affiliates related to the Compounds to develop, manufacture and commercialize Licensed Products for use in the Field; and 

B. Pursuant to Section 5.2(d)(ii) of the Assignment and License Agreement, the Parties contemplated that Shire would provide certain
transitional services to Mirum with respect to the Compounds and Licensed Products. 
 NOW, THEREFORE, in consideration of the foregoing
recitals and the mutual representations, warranties, covenants and promises contained herein, the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows: 

1. DEFINITIONS. 
 Capitalized terms used in this
Agreement (other than the headings of the Sections or Articles) have the following meanings set forth in this Article 1, or, if not listed in this Article 1, the meanings set forth in the Assignment and License Agreement. 

1.1 “Affiliate” means, with respect to a particular Party, a person, corporation, partnership, or other entity that
controls, is controlled by or is under common control with such Party. For the purposes of the definition in this Section 1.1 the word “control” (including, with correlative meaning, the terms “controlled
by” or “under the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity,
whether by the ownership of at least fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. 
 1.2
“Agreement” has the meaning set forth in the Preamble and includes all Transition Services Schedules attached hereto. 

1.3 “Assignment and License Agreement” has the meaning set forth in the Recitals. 

1.4 “Effective Date” means the Effective Date, as such term is defined in the Assignment and License Agreement. 

1.5 “Employment Transfer Date” means February 1, 2019. 

1.6 “FTE Cost” means, with respect to a given month, the applicable Monthly FTE Rate set forth on Exhibit C multiplied
by the applicable number of full time equivalents of Shire and its Affiliates performing Services during such month. 
 1.7
“Losses” means liabilities, costs, expenses (including legal expenses), claims, actions, proceedings, damages, fines and penalties. 

  
 Page 1 

 1.8 “Mirum” has the meaning set forth in the Preamble. 

1.9 “Service” means each individual row of transition services set forth in the Transition Services Schedule. 

1.10 “Service Extension Period” has the meaning set forth in Section 4.1. 

1.11 “Service Term” means, with respect to any Service, the period commencing on the Effective Date, and ending on the
Service Termination Date or such earlier date as may be mutually agreed by the Parties in writing pursuant to Section 4.1. 
 1.12
“Service Termination Date” means, with respect to any Service, the termination date specified with respect to such Service in the Transition Services Schedule or the earlier date on which such Service is completed. 

1.13 “Shire” has the meaning set forth in the Preamble. 

1.14 “Term” has the meaning set forth in Section 4.1. 

1.15 “Transferring Employees” means the employees listed in Exhibit D who will automatically transfer or be offered
employment by Mirum or any of its Affiliates commencing on the Employment Transfer Date. 
 1.16 “Transition Services
Schedule” means the schedule of transition services attached to this Agreement as Exhibit A. 
 2. SERVICES 

2.1 Schedules and Precedence. In accordance with Section 2.2 and the other terms and conditions of this Agreement, during the Term, Shire
agrees to provide to Mirum the Services set forth on the Transition Services Schedule until the applicable Service Termination Date. If there is any inconsistency between the terms of the Transition Services Schedule and the terms of this Agreement,
the terms of this Agreement shall govern. 
 2.2 Performance of Services. 

(a) Shire shall perform or cause its Affiliates to perform all Services in a manner that is based on Shire’s past practice and that is
substantially similar in nature, quality, quantity, scope and timeliness to the analogous services provided by Shire or any of its Affiliates, in connection with the Compounds and Licensed Products during the twelve (12) calendar months prior
to the Effective Date; provided that, if not so previously provided, then such Services shall be performed in a manner substantially similar to similar services provided to Shire’s Affiliates or businesses for similarly situated products. 

(b) Any Information transfer provided for in the Transition Services Schedule need only be provided in such written or electronic format as it
is held by Shire or its Affiliate. Any material transfers provided for in the Transition Services Schedule shall exclude any materials Shire expects to be required for the Existing Trials and other activities of Shire to be conducted prior to the
full transition of activities to Mirum. 
 2.3 Change Order Process. Any change in the nature, quality, quantity, scope or timeliness
of any Service or other amendment to the Transition Services Schedule must be in writing and signed by the Parties. 

  
 Page 2 

 2.4 Service Managers. Each Party shall appoint a representative having the
appropriate qualifications to act as its service manager under this Agreement (the “Service Manager”). Shire’s Service Manager shall initially be Andres Centellas and Mirum’s Service Manager shall initially be Lara
Longpre. The Service Managers shall serve as the primary contact points between the Parties with respect to the conduct of activities under this Agreement. Each Party may replace its Service Manager at any time upon written notice to the other
Party. 
 2.5 Use of Third Parties to Provide Services. Shire may perform any or all Services through agents, subcontractors or
independent contractors; provided that, Mirum’s prior written approval (not to be unreasonably withheld, conditioned or delayed) shall be required if Shire uses any new agents, subcontractors or independent contractors that were not used by
Shire prior to the Execution Date. Notwithstanding the foregoing, Shire shall not be relieved of its obligations under this Agreement by use of such agents, subcontractors or independent contractors. 

3. ASSIGNMENT OF ADDITIONAL ANCILLARY AGREEMENTS 

3.1 Assignment. Subject to any notice or consent requirements thereunder, Shire hereby assigns, transfers and conveys to Mirum all of
Shire’s and its Affiliates’ right, title, and interest in and to the agreements set forth on Exhibit B (the “Additional Assigned Ancillary Agreements”) and Mirum hereby (a) accepts such assignment, transfer and
conveyance and agrees to timely perform, pay and discharge, as and when due, all duties and obligations of Shire and its Affiliates (Mirum and its Affiliates after assignment) under the Additional Assigned Ancillary Agreements to the extent arising
on or after the Execution Date and excluding all liabilities arising from any failure by Shire or its Affiliates to timely perform, pay and discharge, as and when due, all duties and obligations of Shire and its Affiliates under the Additional
Assigned Ancillary Agreements prior to the Execution Date, which shall remain liabilities of Shire or its Affiliates, and (b) agrees to be substituted for Shire or its Affiliate, as applicable, as a party to the Additional Assigned Ancillary
Agreements from and after the Execution Date. 
 3.2 Application of Assignment and License Agreement. Subject to any notice or consent
requirements thereunder, (a) the Additional Assigned Ancillary Agreements are hereby deemed to be Assigned Ancillary Agreements under the Assignment and License Agreement as of the Execution Date and (b) the provisions of the Assignment
and License Agreement (including Section 10.1 and other applicable provisions, but excluding Sections 2.1 and 2.3) applicable to Assigned Ancillary Agreements shall apply with respect to the Additional Assigned Ancillary Agreements; provided
that, in applying this clause (b) any references to the Effective Date in the Assignment and License Agreement shall be treated as references to the Execution Date of this Agreement. 

3.3 Efforts to Complete Assignment. If any of the Additional Assigned Agreements require the consent of the counterparty thereto to
assign such agreement to Mirum or the assignment of such agreement is otherwise not effective, then Shire and its Affiliates will use commercially reasonable efforts, and Mirum will reasonably cooperate with Shire’s efforts, to obtain such
consent or take other reasonable actions (at no cost to Shire) in order to complete the assignment, transfer and conveyance of such Agreement to Mirum pursuant to Section 3.1. 

3.4 Limited License to Perform Services. During the Term, Mirum hereby grants to Shire a
non-exclusive right and license under the Additional Assigned Agreements to the extent necessary for Shire to perform (or have performed) the Services. 

  
 Page 3 

 4. TERM AND TERMINATION. 

4.1 Term. This Agreement shall be effective as of the Effective Date and shall terminate upon the earlier to occur of: (a) the last
date on which Shire is obligated to provide any Service to Mirum in accordance with the terms of this Agreement, (b) the mutual written agreement of the Parties to terminate this Agreement in its entirety, or (c) termination of the
Assignment and License Agreement in accordance with its terms (the “Term”). This Agreement shall terminate with respect to any given Service at the close of business on the last day of the Service Term for such Service;
provided that, if the Parties mutually agree in writing to extend the Service Term for a given Service, this Agreement shall terminate with respect to such Service as of such mutually agreed date (such extension period, the “Service
Extension Period”). In addition, upon fifteen (15) days’ prior written notice, Mirum may terminate any Service that is no longer required to transition activities with respect to the Compounds and Licensed Products to
Mirum; provided that Mirum shall be responsible for reimbursement of any un-cancellable costs incurred or obligated prior to such termination. 

4.2 Effect of Termination or Expiration. Termination or expiration of this Agreement or a given Service shall not affect any rights or
obligations of the Parties under this Agreement that have accrued prior to the date of termination or expiration. Notwithstanding anything to the contrary, the following provisions shall survive any expiration or termination of this Agreement:
Article 1, Article 3, Article 5 (with respect to Services performed, or any un-cancellable costs incurred or obligated, prior to expiration or termination), Article 7, Article 8, Section 10.1 and Article
11. 
 5. PAYMENT TERMS. As consideration for provision of the Services (whether provided before on or after the Effective Date), Mirum shall reimburse
Shire for the applicable FTE Costs plus Shire’s reasonable and documented out-of-pocket costs incurred by or on behalf of Shire or its Affiliates for the conduct of
the Services; provided that, for any such costs incurred during the Service Extension Period, such reimbursement by Mirum shall be 105% of such costs. Shire shall invoice Mirum on a monthly basis for such costs and Mirum shall reimburse Shire the
undisputed portion of each such invoice within thirty (30) days of receipt. If Mirum disputes any invoice, it shall provide written notice to Shire detailing the nature of such dispute within fifteen (15) days of receipt of the applicable
invoice (and, if notice of dispute is not given within such fifteen (15) day period, the applicable invoice shall be deemed accepted and undisputed). The Parties shall cooperate in good faith to resolve any disputes relating to invoices. If the
Parties are unable to resolve an invoice dispute, then either Party may refer the dispute to Grant Thornton (or, if Grant Thornton is unwilling or unable to serve, such other independent accounting firm of national standing as the Parties may
mutually agree, which agreement shall not be unreasonably withheld, conditioned or delayed). The fees and expenses of such accounting firm in resolving such dispute will be borne by the Parties in the same proportion that the aggregate amount of the
disputed items that are unsuccessfully disputed by each Party (as determined by the accounting firm) bears to the total amount of all disputed items. 
 6.
TRANSITION SERVICE RESPONSIBILITIES. 
 6.1 Mutual Responsibilities. The Parties shall use good faith efforts to cooperate with each
other in all matters relating to the provision and receipt of Services. Such cooperation shall include: 
 (a) exchanging information
relevant to the provision of Services hereunder; 
 (b) good faith efforts to mitigate problems interfering with the Services; and 

(c) each Party requiring its personnel to obey any disclosed security regulations and other published policies of the other Party while on the
other Party’s premises. 
 6.2 Mirum Responsibilities. Mirum shall: 

(a) use Commercially Reasonable Efforts to effectuate the transition of the Existing Trials (including sponsorship thereof) to Mirum as
promptly as practicable after the Effective Date; including, if needed, using Commercially Reasonable Efforts to enter into agreements with Third Parties previously working with Shire or its Affiliates in connection with the Existing Trials; and

  
 Page 4 

 (b) make an orderly transition of each Service to its own internal organization or to Third
Party vendors as promptly as reasonably practicable after the Effective Date. 
 6.3 Excused Performance. Shire shall be excused from
performing any obligation under this Agreement to the extent and during the period that Mirum’s failure to perform its obligations under this Agreement materially hinders or prevents Shire’s performance of such obligation. 

7. CONFIDENTIALITY. Any Information disclosed under this Agreement shall be deemed Confidential Information under the Assignment and License Agreement and
subject to the applicable provisions of the Assignment and License Agreement. 
 8. INDEMNIFICATION; LIMITATION ON LIABILITY. 

8.1 Indemnification by Mirum. Mirum shall defend, indemnify, and hold the Shire Indemnitees harmless from and against any and all Losses
which the Shire Indemnitees may suffer, sustain, incur, pay or be put to by reason of or in connection with any Claim by any Transferring Employee against the Shire Indemnitees arising out of or in connection with the deferred Employment Transfer
Date and any employment related Claims asserted by any Transferring Employee after the Employment Transfer Date including any Claim relating to a failure by either Shire or Mirum or any of their respective Affiliates to comply with their obligations
pursuant to Art. 333 ss Swiss Code of Obligations; provided that nothing in this Section shall cause Mirum to be liable for any employment related claims asserted by any Transferring Employee pertaining to period(s) prior to the Effective
Date, which shall remain liabilities of Shire or its Affiliates. 
 8.2 Indemnification Procedures. The indemnification procedures set
forth in Section 10(c) of the Assignment and License Agreement shall be deemed incorporated into, and made a part of, this Agreement, and shall apply to any claims for indemnification brought pursuant to Section 8.1, mutatis
mutandis. 
 8.3 MIRUM’S SOLE REMEDY HEREUNDER IN THE EVENT THE PERFORMANCE OF ANY PARTICULAR SERVICE, WHETHER PERFORMED DIRECTLY BY
SHIRE OR ITS AFFILIATES OR BY A THIRD PARTY DESIGNATED BY SHIRE, FAILS TO COMPLY WITH THE TERMS OF THIS AGREEMENT IS (A) THE PROVISION OF SUCH PARTICULAR SERVICE BY SHIRE CURING THE NON-COMPLIANCE OR
(B) REIMBURSEMENT FOR THE AMOUNTS ACTUALLY PAID BY MIRUM AND RECEIVED BY SHIRE FOR THE PORTION OF THE SERVICE THAT WAS PROVIDED IN A NON-COMPLIANT MANNER. WITHOUT LIMITING THE PRECEDING SENTENCE, IT IS
ACKNOWLEDGED AND AGREED THAT UNDER NO CIRCUMSTANCES SHALL ANY PARTY BE LIABLE FOR LOST PROFITS OR ANY PUNITIVE DAMAGES OR INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ANY BREACH OR
ALLEGED BREACH OF ANY OF THE TERMS HEREOF, INCLUDING DAMAGES ALLEGED AS A RESULT OF TORTIOUS CONDUCT. THE PROVISIONS OF THIS SECTION 8.3 SHALL SURVIVE INDEFINITELY, NOTWITHSTANDING ANY TERMINATION OF ALL OR ANY PORTION OF THIS AGREEMENT. 

9. FORCE MAJEURE. Each Party shall be excused from the performance of its obligations under this Agreement to the extent that such performance is prevented by
force majeure (as defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party
takes reasonable efforts to remove the condition. For purposes of this Agreement, “force majeure” shall include conditions beyond the control of the Parties, including an 

  
 Page 5 

 
act of God, war, civil commotion, terrorism, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of
production facilities or materials by fire, earthquake, storm or like catastrophe. Notwithstanding the foregoing, the payment of amounts due and owing hereunder shall in no event be delayed by the payor because of a force majeure affecting the
payor. 
 10. REPRESENTATIONS AND WARRANTIES 

10.1 EXCEPT AS EXPRESSLY PROVIDED IN THE ASSIGNMENT AND LICENSE AGREEMENT, ANY INFORMATION OR MATERIALS SUPPLIED BY SHIRE ARE SUPPLIED “AS
IS” AND SHIRE MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND WITH RESPECT TO THE SERVICES OR ANY INFORMATION OR MATERIALS, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE,
OR THAT THE USE OF THE INFORMATION OR MATERIALS DOES NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS OF A THIRD PARTY. Mirum assumes all liability for damages which may arise from its use, storage or disposal of such
materials. Shire will not be liable to Mirum for any loss, claim or demand made by Mirum or its Affiliates, or made against Mirum or its Affiliates by any Third Party, due to or arising from the use, handling, storage or disposal of such Information
(except as expressly provided in the Assignment and License Agreement) or materials. 
 11. MISCELLANEOUS 

11.1 Entire Agreement; Amendments. This Agreement, including the Exhibits hereto, and the Assignment and License Agreement sets forth
the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and thereof, and supersedes all prior
agreements and understandings between the Parties with respect to the subject matter hereof and thereof. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed
by an authorized signatory of each Party. If there is any inconsistency between the terms of this Agreement and the Assignment and License Agreement, the Assignment and License Agreement shall govern. 

11.2 Notices. Any notices given under this Agreement shall be in writing, addressed to the Parties at the following addresses, and
delivered by person, by facsimile (with receipt confirmation), or by FedEx or other reputable courier service. Any such notice shall be deemed to have been given: (a) as of the day of personal delivery; (b) one day after the date sent by
facsimile service; or (c) on the day of successful delivery to the other Party confirmed by the courier service. Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below. 

If to Mirum: 

Mirum Pharmaceuticals, Inc. 

12230 El Camino Real, Suite 230 

San Diego, CA 92130 

Attention: Chief Executive Officer 

With a copy (which shall not constitute notice) to: 

Cooley LLP 

4401 Eastgate Mall 

San Diego, CA 92121-1909 

Attention: Kay Chandler 

FAX: +1 858 550 6420 

  
 Page 6 

 If to Shire: 

Shire International GmbH 

Zahlerweg 10 

6300 Zug – Switzerland 

Attention: Legal Department 

With copies (which shall not constitute notice) to: 

Shire 

300 Shire Way 

Lexington, MA 02421 

Attention: Legal Department 

and 
 Morgan,
Lewis & Bockius LLP 
 502 Carnegie Center 

Princeton, NJ 08540-6241 

Attention: Randall Sunberg 

FAX: 1.609.919.6701 

11.3 Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written
consent of the other, except that a Party may make such an assignment without the other Party’s consent to its Affiliates, including in connection with any re-domiciling of such Party or its Affiliates,
or to a Third Party to which the Assignment and License Agreement is assigned. Any permitted assignment shall be binding on the successors of the assigning Party and any successor or assignee of a Party’s rights or obligations hereunder shall,
in writing to the other Party, expressly assume performance of such Party’s rights or obligations under this Agreement. Any assignment or attempted assignment by either Party in violation of the terms of this Section 11.3 shall be null,
void and of no legal effect. 
 11.4 Severability. If any of the provisions of this Agreement are held to be invalid or unenforceable
by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith
effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

11.5 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other
matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time. 

11.6 Independent Contractors. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed
to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties. 

11.7 Governing Law. Resolution of all disputes, controversies or claims arising out of, relating to or in connection with this Agreement
or the performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of New York, U.S., without regard to conflicts of law rules. 

  
 Page 7 

 11.8 No Benefit to Third Parties. Except as provided in Article 8, covenants and
agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns, and they shall not be construed as conferring any rights on any Third Party. 

11.9 Construction of this Agreement. When used in this Agreement, the term “including”, “include” or
“includes” means including, without limiting the generality of any description preceding the term. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular,
the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). References to either Party include the successors and permitted assigns of that Party. The headings of this Agreement are
for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The Parties have each consulted counsel of their choice regarding
this Agreement and have jointly prepared this Agreement, and, accordingly, no provisions of this Agreement shall be construed against either Party on the basis that the Party drafted this Agreement or any provision thereof. If the terms of this
Agreement conflict with the terms of any Exhibit, then the terms of this Agreement shall govern. This Agreement has been prepared in the English language and English shall control its interpretation. 

11.10 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of
which shall constitute together the same document. Counterparts may be signed and delivered by facsimile, or electronically in PDF format, each of which shall be binding when sent. 

{Signature Page Follows} 

  
 Page 8 

 IN WITNESS WHEREOF, the Parties have executed this Agreement m duplicate originals by their proper
officers, effective as of the Effective Date. 
  

									
	MIRUM PHARMACEUTICALS, INC.	 	    	 	SHIRE INTERNATIONAL GMBH
					
	By:	 	 /s/ Chris Peetz
	 		 	By:	 	 /s/ William Standaert

	Name:	 	Chris Peetz	 		 	Name:	 	William Standaert
	Title:	 	President	 		 	Title:	 	Authorized Signatory

  
 Page 9 

 EXHIBIT A 

TRANSITION SERVICES SCHEDULE 
 To the extent
provided for in Section 5.2(d) of the Assignment and License Agreement, those services identified in Exhibit A with an asterisk in the “TSA #” column will be provided at no additional cost to Mirum. 

 

																																															
	 TSA features
	  	 Duration
	  	 Number of FTEs/
contractors
	  	 	  	 	  	 	  	 	  	 	  	 
	 TSA#
	  	 Shire TSA
coordinator
	  	 Service Type
	  	 TSA description
	  	 KPI’s
	  	 Country
providing
service
	  	 Country
receiving
service
	  	 Target Start
Date
	  	 Target
Completion
Date
	  	 Exit Plan
	  	 Name of Shire’s
resource
providing
TSA
	  	 Shire
systems
required
	  	 Data
transfer
TSA?
	  	 Notes / Comments
	  	 TSA duration/
comment
	  	 TSA
duration
(in
months,
starting
from Day
1—for cost
calculation)
	  	 # of
High
Cost
FTEs
	  	 # of
Medium
Cost
FTEs
	  	 # of
Low
Cost
FTEs
	  	 # of
High Cost
Contractors
	  	 #
of
Medium
Cost
Contractors
	  	 # of
Low Cost
Contractors
	  	 Entity
invoiced
	  	 Monthly
Cost per
TSA

	REG-1	  	Erik Bjornson	  	SHP625: Regulatory management of IND and CTAs, and transfer of dossiers	  	 Shire will perform ongoing regulatory management of all regulatory dossiers (39 total: 24 CTAs, 4 active INDs, 8 ODAs, 3 PIPs) ) for up to
3 monthsending with submission of formal notifications of transfer of sponsorship. Shire will provide additional signed documentation as needed to support the transfers of sponsorship for 1 month after the submissions have been made.

Assumptions:
• Buyer will make best efforts to complete acceptance of sponsorship in a timely fashion once data transfer is complete and all requisite
conditions have been met.
• Buyer will provide Shire with timely confirmation (confirmations within 10 business days or less) that the regulatory authorities have acknowledged the transfers of sponsorship.

 
	  	Submission of transfer and acceptance of ownership documentation to IND and CTAs.	  	US	  	US	  	11/5/2018	  	2/15/2019	  	Transfer of sponsorships complete and signed documentation provided (as needed) following transfer submissions.	  	Global Regulatory Lead	  		  	Yes	  		  	3.5 months	  	3.5	  	0.017	  	0.133	  	0.004	  		  		  		  		  	$ 2,853
																								
	REG-2	  	Sunil Kadam	  	SHP626: Regulatory management of IND and CTAs, and transfer of dossiers	  	 Maintenance of open regulatory dossiers (US IND, CTAs in Canada and UK for 201 study) including CSR submission and end-of-trial notifications as required. 
Preparation and submission of IND transfer letter and delivery to buyer for inclusion in their submission.

 
	  	Submission of transfer and acceptance of ownership documentation to IND and CTAs.	  	US	  	US	  	11/5/2018	  	1/31/2019	  	Transfer of sponsorships complete and signed documentation provided (as needed) following transfer submissions.	  	Global Regulatory Lead	  		  	Yes	  		  	3 months	  	3	  	0.004	  	0.013	  		  		  		  		  		  	$ 355
																								
	REG-3	  	Erik Bjornson, Sunil Kadam	  	SHP625/SHP626: Maintenance	  	 Ad-hoc regulatory consulting as requested by Buyer for either SHP625 or SHP626. This includes (but
is not limited to) support of regulatory agency meeting preparation, review of Buyer-prepared documents for regulatory submissions, or participation in strategic discussions. This task includes up to 12 hours over a
3-month period after deal close.
  
	  	Provide consultation to buyer for the first 3months	  		  	US	  	11/5/2018	  	1/31/2019	  	Transfer of sponsorships complete and signed documentation provided (as needed) following transfer submissions.	  	Global Regulatory Lead	  		  		  		  	3 months	  	3	  	0.025	  		  		  		  		  		  		  	$ 864
																								
	REG-4*	  	Shakira Baez	  	SHP625/SHP626: Data transfer	  	 Shire will transfer all Output Submissions folder; Correspondence, Components, Administrative files and other relevant Regulatory documents
that are located in Shire EDMS, and other repository such as Share drive.
  
	  		  		  		  		  	1/31/2019	  		  		  		  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	3 months	  	3	  		  	0.5	  		  		  		  		  		  	
																								
	GDS-1	  	Tom Organ	  	SHP626: Prepare and submit DSUR	  	 Shire will prepare and submit the Development Safety Update Report (DSUR), covering the period of 19 Dec 2017 to 18 Dec 2018, according to
Shire SOPs and processes. The final report will be submitted to the IND no later than 60 days after the end of the reporting period. Buyer will receive a copy of the final DSUR.

 
	  	Submission of final DSUR and delivery of copy to buyer	  		  		  	11/5/2018	  	2/28/2019	  	Complete DSUR and submit to IND; provide copy to buyer	  		  		  		  		  	4 months	  	4	  	0.12	  	0.24	  		  		  		  		  		  	$ 8,172
																								
	GDS-2	  	Nancy Blanchard	  	SHP625/SHP626: Signal detection	  	 Shire to perform signal detection according to Shire’s procedures and provide Buyer with the results. Work will end when all INDs have
been transferred to Buyer.
  
	  	Quarterly meetings for review and agreement on signal assessment	  	US	  	WW	  	11/5/2018	  	2/28/2019	  	INDs transferred to buyer	  		  		  		  		  	4 months	  	4	  	0.0025	  	0.005	  		  		  		  		  		  	$ 171
																								
	DD-1*	  	Kelly Spencer/Melissa Griffin/Arthur Van Leerberghe	  	SHP625: Data Transfer	  	 Transfer all relevant electronic (i.e ncl completed/on going BBD specific clinical and nonclinical databases) and/or paper related to
SHP625 (i.e. Trial Master File) R&D data that is reasonably available and in Sellers’ possession as of the Closing Date, within 6 monthsof the Closing Date to Service Recipient. To the extent CRO data included in the Transferred Assets
is not reasonably practical to be delivered in that time period, Service Provider will reassigned all such data to the Buyer. (SHP625) 
  
	  	Electronic and/or physical transfer (as appropriate) of all materials related to SHP625- Est 7 Nov018. As applicable, to include Letters of formal transfer (N.Rzucidlo) to be completed 1 month after Day 1. As applicable,
consolidation of records from Shire’s EPL archive facility (N.Rzucidlo) to be completed in < 6 months.	  	US	  	US	  		  	4/30/2019	  	N/A	  	R&D Scientific Documentation	  	N/A	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	6 months	  	6	  		  	0.5	  		  		  		  		  		  	
																								
	DD-2*	  	Kelly Spencer/Melissa Griffin	  	SHP625: Materials Transfer (nonclinical)	  	 Transfer all material that is reasonably available and in Sellers’ possession as of the Closing Date, within 6 monthsof the
Closing Date to Service Recipient.
 To the extent any biomaterials (including study tissues and slides, drug substance and drug product, and related records,
reagents and standards) included in the Acquired Assets not delivered at the Closing, Service Provider will deliver all such biomaterials to Service Recipient after the Closing. Service Provider shall be deemed to have complied with its obligation
to deliver such Acquired Assets to Service Recipient if it has made such Acquired Assets available for pick-up by Service Recipient.In the event any biomaterials included in the Acquired Assets are held at
third party vendors, Service Provider will be deemed to have transferred such biomaterials to Service Recipient at the Closing.
  
	  	Electronic and/or physical transfer (as appropriate) of all materials related to SHP625- Est 7Nov2018. As applicable, to include Letters of formal transfer (N.Rzucidlo) to be completed 1 month after Day 1. • As applicable,
consolidation of records from Shire’s EPL archive facility (N.Rzucidlo) to be completed in < 6 months.	  	US	  	US	  		  	4/30/2019	  	N/A	  	R&D Scientific Documentation	  	N/A	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	6 months(3m?)	  	6	  		  	0.5	  		  		  		  		  		  	
																								
	DD-3	  	Kelly Spencer / John McNulty	  	SHP625: Preclinical Program Support	  	Make introduction to and transfer ownership of work (transfer of completed / ongoing reports and any related materials to the buyer)with the CRO responsible for providing Toxicology support to the SHP625 program, within
4 monthsof closing date to recipient (more detail in KPI) . The Shire’s activity and support of these studies relate to, but not exclusively the on-going bioanalytical reports, toxicology
reports.	  	 (i) pass of oversight of ongoing juvenile DRF study (CRL); pass of protocol (agency reviewed/commented) for pivotal juvenile toxicity study
(CRL/Ashland) -final report November. Propose Buyer establish a MSA with CRL in order to perform the pivotal juvenile study in support of the ongoing PIP
  

(ii) pass of ongoing DRF transgenic mouse study (Covance) and information of planned path forward-option to review/finalziation by Buyer (Shire to complete
Feb2019). Propose Buyer establish a MSA with Covance to continue pivotal transgeneic mouse study
  

(iii) pass of DRF early development information for 2-year carcinogenicity studies
(timing-PMC)
 1 monthsFrom Day 1, Buyer and Shire to agree scedules for the regular transfer of knowledge, the
activity of which is completed by the duration of the TSA, or before.
  
	  	US	  	US	  	11/5/2018	  	2/28/2019	  	N/A	  	NCD-Toxicology	  	N/A	  		  		  	4 months	  	4	  		  	0.1	  		  		  		  		  		  	$ 1,350
																								
	DD-4	  	Kelly Spencer / Marita Larsson Cohen	  	SHP625: Clinical Program Support	  	Vendor Oversight—Provide Bioanalytical and Biomarker Development (BBD) support to the SHP625 program. 
To ensure business continuity and established partnering in support of SHP625, Shire will oversee the CROs performing
biomarker and bioanalytical work, and will provide bioanalytical support to the Buyer during the transition period. Shire will work with the Buyer and CROs to ensure transfer of ownership of completed work and transfer of knowledge for ongoing
activities. 
- additional details on activities reviewed with Mirum on Jan 7—presentation Shire-Mirum BBD activities 07Jan2019_to share.pptx	  	 Propose Buyer establish a MSA with following vendors to enable SOW transfer, as desired: BioAglytix, Prometheus, EGL
Genetics/Eurofins, Envigo, Frontage, Q2 Solutions. Propose buyer to obtain full contract transfer of Cinnciniatti Children’s Hospital (CCH) and MRM Proteomics

i. Assume contracts for ongoing LUM001 (SHP625) Phase II Clinical Trials

LUM001-301, finishing 

LUM001-303, ongoing study 

LUM001-304, ongoing study 

LUM001-305, ongoing study 

LUM001-501, ongoing study
  

a. Cincinnati Children’s Hospital (CCH), all studies 

b. Envigo CRS, Inc., all studies 
 c.
Bioagilytix Labs, LLC, all studies 
 d. MRM Proteomics, LUM001-501 Exome sequencing and
bioinformatics of protein analysis 
 e. Q Squared Solutions Expressions Analysis, genomic biomarkers

ii. Assume work for LUM001 (SHP625) Phase III Clinical Trials (none started) a. Envigo CRS, Inc, methods validated, to move from CCH

b. Frontage Laboratories, methods validated, alternate site to move from CCH, SHP625-306 work proposed
but not started
 c. Prometheus Laboratories, Inc.: proposed SHP625 Ph III, not started 

iii. Assume work for LUM002 (SHP626), work suspended 

a. Envigo CRS, Inc., wrapping up SHP626-201 study

 
	  	US	  	US	  	11/5/2018	  	1/31/2019	  	N/A	  	NCD-BBD	  	N/A	  		  		  	3 months	  	3	  		  	0.75	  		  		  		  		  		  	$ 12,659
																								
	DD-5*	  	Kelly Spencer/Melissa Griffin/Holly Oakley	  	SHP626: Data Transfer	  	 Transfer all relevant electronic (i.e ncl completed/on going BBD specific clinical and nonclinical databases) and/or paper (i.e. Trial
Master File) R&D data that is reasonably available and in Sellers’ possession as of the Closing Date, within 6 monthsof the Closing Date to Service Recipient. To the extent CRO data included in the Transferred Assets is not reasonably
practical to be delivered in that time period, Service Provider will reassigned all such data to the Buyer. (SHP626) 
  
	  	Electronic and/or physical transfer (as appropriate) of all materials related to SHP626- Est 21 Nov018. As applicable, to include Letters of formal transfer (N.Rzucidlo) to be completed 1 month after Day 1. As applicable,
consolidation of records from Shire’s EPL archive facility (N.Rzucidlo) to be completed in < 6 months.	  	US	  	US	  		  	4/30/2019	  	N/A	  	R&D Scientific Documentation	  	N/A	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	6 months	  	6	  		  	0.5	  		  		  		  		  		  	
																								
	DD-6*	  	Kelly Spencer/Melissa Griffin	  	SHP626: Materials Transfer	  	 Transfer all material that is reasonably available and in Sellers’ possession as of the Closing Date, within 6 monthsof the
Closing Date to Service Recipient. 
To the extent any biomaterials (including study tissues and slides, drug substance and drug product, and related records, reagents and standards) included in the Acquired Assets not delivered at the Closing,
Service Provider will deliver all such biomaterials to Service Recipient after the Closing. Service Provider shall be deemed to have complied with its obligation to deliver such Acquired Assets to Service Recipient if it has made such Acquired
Assets available for pick-up by Service Recipient. In the event any biomaterials included in the Acquired Assets are held at third party vendors, Service Provider will be deemed to have transferred such
biomaterials to Service Recipient at the Closing.
  
	  	Electronic and/or physical transfer (as appropriate) of all materials related to SHP626- Est 21Nov2018. As applicable, to include Letters of formal transfer (N.Rzucidlo) to be completed 1 month after Day 1. • As applicable,
consolidation of records from Shire’s EPL archive facility (N.Rzucidlo) to be completed in < 6 months.	  	US	  	US	  		  	4/30/2019	  	N/A	  	R&D Scientific Documentation	  	N/A	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	6 months	  	6	  		  	0.5	  		  		  		  		  		  	
																								
	DD-7	  	Melissa Griffin	  	SHP625/SHP626: Archiving	  	 Continued GxP archiving of paper/physical R&D materials (beyond 31 Jan 2019) at pass-through costs until buyer’s establishment of
own GxP archiving contract(s).
  
	  		  		  		  	11/5/2018	  	4/30/2019	  	Buyer’s establishment of their own contracts for GxP archiving	  		  		  		  		  	6 months	  	6	  		  		  	0.006	  		  		  		  		  	$ 40
																								
	CDO-1	  	Jeremy Chadwick	  	SHP625: Clinical Program Management	  	 Oversight of project management activities for the 4 ongoing Phase 2 studies (SHP625-303, 304, 305,
501) until knowledge transfer completed.
  
	  	Complete knowledge transfer to manage and oversee the clinical study activities of the Phase 2 studies, as acknowledged by buyer.	  	USA	  	USA	  	11/5/2018	  	1/31/2019	  	Buyer’s counterpart acknowledging complete transition	  	GCOL	  	Systems as defined in data transfer forms	  		  	Contingent on Transfer of FTEs/Contractors	  	3 months	  	3	  	0.5	  		  		  		  		  		  		  	$ 17,285
																								
	CD-1	  	Thomas Jaecklin	  	SHP625: Clinical Medical oversight and management	  	 Clinical Medical oversight and management of the 4 ongoing Phase 2 studies (SHP625-303, 304, 305,
501) until knowledge transfer completed.
  
	  	Complete knowledge transfer to manage and oversee the clinical medical aspects of the Phase 2 studies, as acknowledged by buyer.	  	Switzerland	  	USA	  	11/5/2018	  	1/31/2019	  	Buyer-Shire agree transfer is complete	  	Global Clinical Development Lead	  	Systems as defined in data transfer forms	  		  	Contingent on Transfer of FTEs/Contractors	  	3 months	  	3	  	1.0	  		  		  		  		  		  		  	$ 34,569
																								
	CDO-4	  	Jeremy Chadwick	  	SHP625: Clinical Program Management	  	 Clinical Project Management and oversight of study conduct, oversight and management of vendors and CRO for the 4 ongoing Phase 2 studies (SHP625-303, 304, 305, 501) until knowledge transfer completed.
  
	  	Complete knowledge transfer to manage and oversee the clinical study activities of the Phase 2 studies, as acknowledged by buyer.	  	USA	  	USA	  	11/5/2018	  	2/28/2019	  	Buyer’s counterpart acknowledging complete transition	  	Sr Clinical Project Manager	  	Systems as defined in data transfer forms	  		  	Contingent on Transfer of FTEs/Contractors	  	4 months	  	4	  		  	1.0	  		  		  		  		  		  	$ 16,879
																								
	CDO-5	  	Courtney Bryant	  	SHP625: Clinical Program Management	  	 Clinical Administrative tasks (meeting organization, agendas, minutes, tracker and system review and completion), until knowledge transfer
completed.
  
	  	Complete knowledge transfer to manage and oversee the admin clinical study activities of the Phase 2 studies, as acknowledged by buyer.	  	USA	  	USA	  	11/5/2018	  	2/28/2019	  	Buyer’s counterpart acknowledging complete transition	  	CRA	  	Systems as defined in data transfer forms	  		  	Contingent on Transfer of FTEs/Contractors	  	4 months	  	4	  		  		  	0.3	  		  		  		  		  	$ 1,924
																								
	CDO-6	  	Michael Hoffman	  	SHP625: Clinical Scientific Writing	  	 Clinical Scientific Writing management and oversight of required clinical documentation for the 4 ongoing Phase 2 studies (SHP625-303, 304, 305, 501), as well as delivery of existing finalized, published reports, until knowledge transfer completed.
  
	  	Completed knowledge transfer for SHP625 clinical documentation, as acknowledged by buyer.	  	USA	  	USA	  	11/5/2018	  	12/31/2018	  	Buyer-Shire agree transfer is complete	  	clinical scientific writer	  	Systems as defined in data transfer forms	  	Yes	  		  	2 months	  	2	  		  	0.2	  		  		  		  		  		  	$ 3,376
																								
	CDO-7*	  	Wendy Beeby	  	SHP625: Data Transfer	  	Delivery of all product TMF documentation - mixed media and paper	  	 All TMF assets delivered successfully to buyer - buyer assumes all responsibility for TMF maintenance upon confirmation

 
	  	USA	  	USA	  		  	2/28/2019	  	Complete transfer of all documentation	  	Clinical Document Mgr	  	Systems as defined in data transfer forms	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	4 months	  	4	  	0.3	  		  		  		  		  		  		  	
																								
	CDO-8*	  	Mike Hale	  	SHP625: Data Transfer	  	 Data transfer of all Biostats assets and Biostats knowledge transfer to buyer - provide point in time copy - when sponsorship is
transferred then final Db will be transferred - this TSA represents the Final data delivery
  
	  	All data assets successfully transferred to buyer with buyer acceptance	  	USA	  	USA	  		  	2/28/2019	  	Completion of transfer of all documentation and knowledge	  	Biostats Project Lead/ Programming Project Lead	  	Systems as defined in data transfer forms	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	4 months	  	4	  	0.5	  		  		  		  		  		  		  	
																								
	CDO-9*	  	Deb Jameson	  	SHP625: Data Transfer for 306	  	 Study SHP625-306: Transfer all IMP Supply Chain Maps, Packaging, Labeling, Distribution info, and
Inventory data if applicable
  
	  	Quarterly meetings for review and agreement on signal assessment	  	USA	  	USA	  		  	2/28/2019	  	Completion of transfer of all documentation	  	Clinical Supplies Team lead	  	Systems as defined in data transfer forms	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	4 months	  	4	  	0.1	  		  		  		  		  		  		  	
																								
	CDO-10*	  	Deb Jameson	  	SHP625: Data Transfer for Phase 2 studies	  	SHP625 Phase 2 studies: Transfer all IMP Supply Chain Maps, Packaging, Labeling, Distribution info, and Inventory data if applicable	  	 Transfer all relevant electronic (i.e inventory records) and/or paper (i.e. Batch Records) R&D data that is reasonably available and in
Sellers’ possession as of the Closing Date, within 4 monthsof the Closing Date to Service Recipient.
  
	  	USA	  	USA	  		  	2/28/2019	  	Completion of transfer of all documentation	  	Clinical Supplies Team lead	  	Systems as defined in data transfer forms	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	4 months	  	4	  	0.1	  		  		  		  		  		  		  	
																								
	CDO-11	  	Mike Hale	  	SHP625: Ongoing study activities	  	 Biostatistics support: SAP review, DRM, SRT, meetings, etc until knowledge transfer completed

 
	  	Buyer’s counterpart acknowledging complete knowledge transfer	  	USA	  	USA	  	11/5/2018	  	2/28/2019	  	Transfer complete	  	Biostats Project Lead/ Programming Project Lead	  	Systems as defined in data transfer forms	  		  		  	4 months	  	4	  		  	0.35	  		  		  		  		  		  	$ 5,908
																								
	CDO-12	  	Jeremy Chadwick	  	SHP626: Clinical trial management	  	 Shire will complete knowledge transfer for all 626 studies 
Shire will complete all activities for ongoing study SHP626-201, including: 
• Complete close-out visit reports 
• Complete study drug accountability 
• Complete TMF and transfer 
• Complete TFLs

• Complete abbreviated CSR 
• Vendor close-outs 
• Clinical project management 
• biostatistical analysis 
• final published CSR
  
	  	Completion of activities as noted.	  	USA	  	USA	  	11/5/2018	  	1/31/2019	  	Complete knowledge transfer and complete study (SHP626-201) activities.	  	Clinical Programs Lead	  	Systems as defined in data transfer forms	  	Yes	  		  	3 months	  	3	  	1.87	  	1.50	  	0.50	  	0.50	  	0.50	  		  		  	$ 118,721
																								
	CDO-13*	  	Diane Piper	  	SHP626: Data Transfer	  	 Data transfer of all Data Management assets. Knowledge transfer to buyer - provide point in time copy - when sponsorship is transferred
then final Db will be transferred - this TSA represents the Final data delivery.
  
	  	All Data management assets successfully transferred to buyer with buyer acceptance	  	USA	  	USA	  		  	2/28/2019	  	Completion of transfer of all documentation and knowledge	  	Lead Clinical data mgr	  	Systems as defined in data transfer forms	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	4 months	  	4	  	0.5	  		  		  		  		  		  		  	
																								
	CDO-14*	  	Wendy Beeby	  	SHP626: Data Transfer	  	Delivery of all product TMF documentation - mixed media and paper	  	 All TMF assets delivered successfully to buyer - buyer assumes all responsibility for TMF maintenance upon confirmation

 
	  	USA	  	USA	  		  	2/28/2019	  	Completion of transfer of all documentation and knowledge	  	Clinical Document Mgr	  	Systems as defined in data transfer forms	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	4 months	  	4	  	0.3	  		  		  		  		  		  		  	
																								
	CDO-15*	  	Mike Hale	  	SHP626: Data Transfer	  	 Data transfer of all Biostats assets - Biostats knowledge transfer to buyer - provide point in time copy - when sponsorship is transferred
then final Db will be transferred - this TSA represents the Final data delivery
  
	  	All data assets successfully transferred to buyer with buyer acceptance	  	USA	  	USA	  		  	2/28/2019	  	Completion of transfer of all documentation and knowledge	  	Biostats Project Lead/ Programming Project Lead	  	Systems as defined in data transfer forms	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	4 months	  	4	  	0.5	  		  		  		  		  		  		  	
																								
	CDO-16*	  	Diane Piper	  	SHP626: Data Transfer	  	Data transfer of all Data Management assets. Knowledge transfer to buyer.	  	 All Data management assets successfully transferred to buyer with buyer acceptance

 
	  	USA	  	USA	  		  	2/28/2019	  	Completion of transfer of all documentation and knowledge	  	Lead Clinical data mgr	  	Systems as defined in data transfer forms	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	4 months	  	4	  	0.3	  		  		  		  		  		  		  	
																								
	CDO-17*	  	Deb Jameson	  	SHP626: Data Transfer for 201	  	Study SHP626-201: Transfer all IMP Supply Chain Maps, Packaging, Labeling, Distribution info, and Inventory data if applicable	  	 Transfer all relevant electronic (i.e inventory records) and/or paper (i.e. Batch Records) R&D data that is reasonably available and in
Sellers’ possession as of the Closing Date, within 4 monthsof the Closing Date to Service Recipient.
  
	  	USA	  	USA	  		  	2/28/2019	  	Completion of transfer of all documentation	  	Clinical Supplies Team lead	  	Systems as defined in data transfer forms	  	Yes	  	TSA billed at zero cost. FTE allocation is for internal purposes only.	  	4 months	  	4	  	0.3	  		  		  		  		  		  		  	
																								
	QAC-1	  	Christine Sahagian	  	SHP625: Quality Assurance and Compliance	  	 Provide QA&C oversight on ongoing studies and compliance support (typical QA&C involvement in an ongoing clinical program - e.g.
available for advice / guidance as needed) needed until complete transfer
  
	  	Buyer’s counterpart acknowledging complete knowledge transfer	  	USA	  	USA	  	11/5/2018	  	2/28/2019	  	Transfer complete	  	QA&C Lead	  	Systems as defined in data transfer forms	  		  		  	4 months	  	4	  		  	0.2	  		  		  		  		  		  	$ 3,376
																								
	QAC-2	  	Christine Sahagian	  	SHP626: Quality Assurance and Compliance	  	 Provide QA&C oversight on ongoing studies and compliance support (typical QA&C involvement in an ongoing clinical program - e.g.
available for advice / guidance as needed) needed until complete transfer
  
	  	Buyer’s counterpart acknowledging complete knowledge transfer	  	USA	  	USA	  	11/5/2018	  	2/28/2019	  	Transfer complete	  	QA&C Lead	  	Systems as defined in data transfer forms	  		  		  	4 months	  	4	  		  	0.1	  		  		  		  		  		  	$ 1,688
																								
	CD-2	  	Mary Corcoran	  	SHP625: Compassionate Use	  	 Shire will provide the required review/approval of the application and IMP resupply (if approved) for the current PFIC patient receiving
SHP625 through a compassionate use/named patient program at Pr. Jankowska’s site in Poland. 
- Two agreements in scope between Shire/Investigator and Shire/Hospital (no existing agreements with 3rd party)

 
	  	Application review and re-supply provided.	  	USA	  	USA	  	11/5/2018	  	1/31/2019	  	Completion of application review and resupply (if approved)	  	Head of Development Planning and Compassionate Use	  		  		  		  	3 months	  	3	  	0.1	  		  		  		  		  		  		  	$ 2,593
																								
	CD-3	  	Melissa Palmer	  	SHP626: Publications	  	In order to comply with clinical trial transparency requirements, Shire will support publication of the SHP626-201 study results. Shire will submit an abstract of the study results for
presentation at the European Association for the Study of the Liver (EASL) 2019 Annual Meeting. In conjunction with the publications vendor (Oxford PharmaGenesis), Shire will prepare the full manuscript for the study results, submit the manuscript
to a peer-reviewed open access journal for publication, and make any necessary revisions and resubmissions. Direct costs for submission fees and open access fees will be passed through to Mirum.	  	Abstract submission. Manuscript submission and resubmission (if needed).	  	USA	  	USA	  	11/5/2018	  	4/30/2019	  	Completion of submissions	  	Global Development Lead	  		  		  	Shire has agreed not to pass through costs for Pharmagenesis to Mirum. Given additional workload for the Shire team, the FTE estimate was revised	  	6 months	  	6	  	0.05	  	0.02	  		  		  	0.13	  		  		  	$ 4,346
		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  	$237,130

 Notes: 
 Any “Target Start
Date” that occurred in the past was the actual start date and will be billed accordingly. 
 Out of pocket costs are not accounted for and will be
billed separately in accordance with the Agreement. 

																																																	
	 TSA features
	  	 Duration
	  	 Number of FTEs/
contractors
	  	 
	 TSA#
	  	 Function
	  	 Shire TSA
coordinator
	  	
The buyer TSA
coordinator
	  	 Service Type
	  	 TSA description
	  	 KPI’s
	  	 Country providing
service
	  	 Country receiving
service
	  	 Target Start Date
	  	 Target Completion
Date
	  	 Exit Plan
	  	
Name of Shire’s
resource providing
TSA
	  	 Shire systems required
	  	 Notes / Comments
	  	 TSA duration/
comment
	  	
TSA duration
(in months, 
starting
from Day 1 - for cost
calculation)
	  	 # of
High Cost
FTEs
	  	 # of
Medium Cost
FTEs
	  	 # of
Low Cost
FTEs
	  	 # of
High Cost
Contractors
	  	 #
of
Medium Cost
Contractors
	  	 # of
Low Cost
Contractors
	  	 Entity invoiced
	  	 Monthly Cost per
TSA
Me

	1	  	Corporate Services (U.S. only)	  	Kendra Renninger	  	Lara Longpre	  	Purchasing and Accounts Payable	  	 Support indirect purchasing activities (U.S. only) as follows:

- Issuance of purchase orders;

-  receipt of invoices;

-  payment of invoices by Shire

-  indirect spend transition activities (i.e. Shire A/P contract to work with a specificed Mirum
contrat to ensure invoices are paid by the right party after the TSA ends)
  
	  		  	US	  	US	  	11/5/2018	  	2/28/2019	  	All MSAs transferred or established and activities transferred to Mirum	  	Kendra Renninger	  	N/A	  		  	3 months	  	3	  		  		  	0.25	  		  		  		  		  	$1,603.35
	2	  	Finance R&D and Corporate Services (U.S. only)	  	Lindsay Carver	  		  	Reporting and Administration	  	 Manage monthly analysis necessary to operate TSA; Finance to compile monthly indirect / third party costs incurred by Shire on behalf of
the buyer and prepare manual billing to the buyer for reimbursement; buyer shall reimburse Shire within 30 days of invoicing
  
	  		  	US	  	US	  	11/5/2018	  	2/28/2019	  	All MSAs transferred or established and activities transferred to Mirum	  	Lindsay Carver	  	N/A	  		  	3 months	  	3	  		  	0.25	  		  		  		  		  		  	$4,219.77
	3	  	Finance R&D	  	Lindsay Carver	  		  	Cut-over process	  	 Provide support in the transition of purchase orders for cut-over (reconciliation assessment)

-  identify transitioning POs, confirm work completed and remaining amount (PO value) to transfer

 
	  		  	US	  	US	  	11/5/2018	  	2/28/2019	  	All MSAs and Pos transitioning identified and provided to Mirum	  	Lindsay Carver	  	N/A	  		  	1 month	  	1	  		  	0.25	  		  		  		  		  		  	$4,219.77
	4	  	Legal	  	Jeff Smith	  		  	Cut-over process	  	 Provide support in the transfer of contracts, which includes locating, reviewing, and uploading relevant contracts to be transferred

 
	  		  	US	  	US	  	+1 month post effective date of TSA	  	+1 month post effective date of TSA	  	All in scope contracts transferred and or assigned	  	Jeff Smith	  	N/A	  		  	1 month	  	1	  		  	0.1	  		  		  		  		  		  	$1,687.91

 Notes: 
 Any “Target Start
Date” that occurred in the past was the actual start date and will be billed accordingly. 
 Out of pocket costs are not accounted for and will be
billed separately in accordance with the Agreement. 

																																																	
	 TSA features
	  	 Duration
	  	 Number of FTEs/
contractors
	  	 	  	 
	 TSA#
	  	 Function
	  	 Shire TSA
coordinator
	  	 the buyer
TSA
coordinator
	  	 Service Type
	  	 TSA description
	  	 KPI’s
	  	 Country
providing
service
	  	 Country
receiving
service
	  	 Target Start
Date
	  	 Target
Completion
Date
	  	 Exit Plan
	  	 Name
of
Shire’s
resource
providing
TSA
	  	 Shire
systems
required
	  	 Notes /
Comments
	  	 TSA
duration/
comment
	  	 TSA
duration
(in
months,
starting
from Day
1—for cost
calculation)
	  	 # of
High
Cost
FTEs
	  	 # of
Medium
Cost
FTEs
	  	 # of
Low
Cost
FTEs
	  	 # of
High Cost
Contractors
	  	 #
of
Medium
Cost
Contractors
	  	 # of
Low Cost
Contractors
	  	 Entity
invoiced
	  	 Monthly Cost
per TSA

	1	  	CMC	  	T.K.	  		  	API	  	Manage GMP SMB separation at Carbogen; Update API specification	  	Participate in weekly meetings w/Carbogen Amcis; provide all the documents and write-ups for API spec change justification to Mirum	  	US	  	US	  	11/5/2018	  	3 months	  	 Attend weekly calls to support knowledge transfer. End of February 2019 target transition date

 
	  	PDTS - CMC Lead	  	NA	  		  		  	3	  	0.2	  		  		  		  		  		  		  	$6,913.87
																									
	2	  	CMC	  	T.K.	  		  	Drug Product	  	 Ph2 supply supply management at various CMOs

-  Knowledge transfer and on-going management of Ph2 clinical
trial material
	  	Ship the dilunet from Almac to Qoutient to meet the supply demand; attend weekly meetings at Qoutient	  	US	  	US	  	11/5/2018	  	3 months	  	Attend weekly calls to support knowledge transfer. End of February 2019 target transition date	  	PDTS - CMC Lead	  	NA	  		  		  	3	  	0.1	  		  		  		  		  		  		  	$3,456.94
																									
	3	  	CMC	  	T.K.	  		  	Analytical	  	 Provide analytical support to both DS and DP – to support ongoing stability studies etc.

-  DS and DP knowledge transfer

-  providing nessesary documents (technical specifications)
	  	 Manage API stability programs for API at Carbogen and the Phase 2 DP at BioDuro and the Phase 3 DP at Unither: ensure samples are tested
per stability schdules and results are received and reviewed and all analytical issues such as OOS are investigated approritaely in a timely manner
  
	  	US	  	US	  	11/5/2018	  	3 months	  	Attend weekly calls to support knowledge transfer. End of February 2019 target transition date	  	PDTS - CMC Lead	  	NA	  		  		  	3	  	0.1	  		  		  		  		  		  		  	$3,456.94
																									
	4	  	CMC	  	T.K.	  		  	QA	  	 Provide QA support to ensure the supply of study drug for Ph2 trials

-  release of Ph3 clinical batches - campiagn number 2

-  provide QA of nessesary documents

 
	  	ensure that the drug supply meets the phase approriate complaince criteria; support any deviation and the follow up action items for the clinical trial materials	  	US	  	US	  	11/5/2018	  	3 months	  	Attend weekly calls to support knowledge transfer. End of February 2019 target transition date	  	PDTS - CMC Lead	  	NA	  		  		  	3	  	0.1	  		  		  		  		  		  		  	$3,456.94
		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  		  	$17,284.68

 Notes: 
 Any “Target Start
Date” that occurred in the past was the actual start date and will be billed accordingly. 
 Out of pocket costs are not accounted for and will be
billed separately in accordance with the Agreement. 

 EXHIBIT B 

ADDITIONAL ASSIGNED ANCILLARY AGREEMENTS 

(see attached) 
  

 

 

 

 

 

 

 

 

 

 EXHIBIT C 

FTE COSTS 
  

			
	 	  	FTE Cost Category
	Manager	  	Medium
	Director	  	High
	Sr Professional I/ Supervisor	  	Medium
	Sr Support/Tech IV	  	Low
	Vice President	  	High
	Sr Director	  	High
	Associate Director	  	Medium
	Professional II	  	Low
	Professional I	  	Low
	Support II/Tech III	  	Low
	Support I/Tech II	  	Low
	Lead Support/Tech V	  	Low
	Tech I	  	Low

  

					
	FTE Cost Category	  	Monthly FTE
Rate (USD)	 
	 Low
	  	 	6,413.41	 
	 Medium
	  	 	16,879.07	 
	 High
	  	 	34,569.36	 

 EXHIBIT D 

TRANSFERRING EMPLOYEES 
 Thomas Jaecklin 

Arthur Van Leerberghe

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]